Photoswitch protein
The scMagnet system, which connects pMag and nMag in series, addresses the limitations of conventional photoswitch proteins by enhancing protein binding and dissociation efficiency, achieving high photoinduction efficiency and minimizing leakage activity, thus providing a robust tool for optogenetic control.
Patent Information
- Application Number
- PCT/JP2024/017063
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-10
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-14
AI Technical Summary
Conventional photoswitch proteins, such as the Vivid (VVD) protein, face challenges with low binding affinity and inability to selectively control protein interactions due to forming homodimers, limiting their efficiency in controlling protein binding and dissociation processes.
The development of a single-molecule optical switch protein, scMagnet, where pMag and nMag are connected in series, allowing for improved control of protein binding and dissociation by modifying the amino acids in the α-helix region and flavin-binding domain, enabling efficient light-dependent dimerization and dissociation.
The scMagnet system significantly enhances the efficiency of protein binding and dissociation, demonstrating over 10 times higher photoinduction efficiency compared to conventional systems and nearly eliminates leakage activity, making it a versatile tool for optogenetic control of split proteins.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002 
Figure 00000057_0000
Abstract
Description
Photoswitching proteins
[0001] The present invention relates to a photoreceptor protein (photoswitch protein) that can control the binding and dissociation of interacting proteins.
[0002] Proteins, which are biological materials, perform various functions in living organisms. For example, protein-protein interactions are involved in regulating systems fundamental to life, such as intracellular signal transduction and material transport. With the recent advances in optogenetics, techniques for controlling protein-protein interactions in living organisms through optical manipulation have been developed, and photoswitch proteins, for example, have attracted attention. Photoswitch proteins were initially reported as protein pairs whose binding and dissociation are controlled by turning light on and off (Patent Document 1). Through the binding and dissociation of photoswitch proteins through optical manipulation, various intracellular phenomena, such as signal transduction, genome editing, and gene expression, can be controlled (Non-Patent Document 1 and Non-Patent Document 2).
[0003] Vivid (VVD), a protein derived from Neurospora Crassa, rapidly forms homodimers upon blue light irradiation (Non-Patent Document 3). VVD, consisting of approximately 150 amino acids, has a smaller molecular weight than previously reported photoreceptor-based dimerization proteins, facilitating precise molecular design. Furthermore, the cofactor (flavin adenine dinucleotide) required for VVD activity is present in eukaryotic cells, making it highly usable for functioning in mammalian cells. However, VVD has problems such as low binding affinity upon light irradiation and the inability to select binding partners due to the formation of homodimers.
[0004] To solve the above-mentioned problems with VVD, the present inventors discovered that modifying amino acids in the N-terminal α-helix of VVD allows for control of the dimerization efficiency, and modifying amino acids adjacent to the flavin-binding domain controls the dimer dissociation rate. Furthermore, they demonstrated that by adding different amino acid modifications to each of the dimer-forming pairs of VVD, dimers can be formed between VVD proteins with different modifications (Patent Document 1, Non-Patent Document 1). Hereinafter, VVD proteins with these different amino acid modifications are referred to as "magnets," and protein control systems using magnets are also referred to as "magnet systems."
[0005] The magnet system developed by the inventors consists of a VVD in which at least one amino acid at the contact region during dimer formation has been substituted with a basic amino acid (a positively charged amino acid) (this modified VVD is also referred to as "positive magnet (pMag)") and a VVD in which an acidic amino acid (a negatively charged amino acid) has been substituted (this modified VVD is also referred to as "negative magnet (nMag)"). The pMag / nMag pair is expected to be used as a photoswitch protein that overcomes the above-mentioned problems of wild-type VVD. However, the binding efficiency between interacting proteins using two independent molecules of pMag and nMag depends on the molecular interaction frequency, and when a two-molecule magnet system is used in cells, it depends on the intracellular concentration of the magnet protein. Thus, although the magnet system shows improved control efficiency, there is still room for further improvement in terms of increasing the interaction frequency.
[0006] Patent Publication No. 2015-165776
[0007] Kawano et al., Nature Chemical Biology 12:1059-1064 (2016). Kawano et al., Nature Communications 6:6256 (2015). Zoltowski et al., Science 316:1054-1057 (2007). Nihongaki et al., Nat. Biotechnol. 33:755-760 (2015).
[0008] In view of the above circumstances, an objective of the present invention is to provide a photoswitching protein that can control protein binding and dissociation more efficiently than conventional photoswitching proteins (for example, magnets).
[0009] To address the above-mentioned challenges, we constructed a single-molecule photoswitch protein by tandemly linking the pMag and nMag molecules that make up the magnet. We found that this dramatically improved the efficiency of controlling the binding and dissociation of split proteins (protein fragments originally split into single proteins so that they can reassemble) compared with conventional bimolecular photoswitches. Hereinafter, single-molecule photoswitch proteins consisting of VVD proteins or their variants (e.g., pMag and nMag) linked in tandem are also referred to as "scMagnets." We designed scMagnets based on the three-dimensional structural model of pMag and nMag. When pMag and nMag are directly linked, the N- and C-terminal fragments of each split protein bound to pMag and nMag are estimated to be at least 6 nm apart, based on the structural model of pMag and nMag in the dark (Fig. 1a). Therefore, self-reassociation of split proteins in the dark is thought to be suppressed by linking pMag and nMag in a tandem arrangement (Fig. 1a). On the other hand, based on the structural model of the VVD dimer (a dimer consisting of pMag and nMag) under light irradiation, the N-terminus of pMag and the C-terminus of nMag are estimated to be located within 1 nm of each other, which is thought to promote rebinding of the split proteins (Fig. 1b). Based on these considerations, the inventors hypothesized that scMagnet undergoes a significant structural change from an open to a closed conformation in a light-dependent manner, and that the intermolecular interaction between pMag and nMag under light irradiation can very efficiently control the binding and dissociation of each protein (e.g., each fragment of a split protein) bound to pMag and nMag (Fig. 1c).
[0010] In fact, the inventors investigated the utility of scMagnet using split photoactivated Cas9 endonuclease (PA-Cas9) (Non-Patent Document 4) under experimental conditions where conventional two-molecule photoswitching systems do not function well (e.g., environments where the expression level of the photoswitching protein is low). The results showed that the activity of scPA-Cas9, a single-molecule photoswitching protein, exhibited over 10 times the photoinduction efficiency under light irradiation compared to the activity of PA-Cas9, a two-molecule photoswitching system, and showed very low leakage activity (activity that occurs even in the dark). Furthermore, the scMagnet system efficiently induced not only the activity of the split Cas9 endonuclease but also the activity of split Cre recombinase, split Flp recombinase, and split Vav2 (a guanine nucleotide exchange factor) in a light-dependent manner (inducing light-dependent activation with a dynamic range of over 100-fold), with almost no leakage activity. Therefore, the scMagnet system of the present invention is a highly versatile system for optogenetically controlling the rebinding and dissociation of various split proteins.
[0011] It was also confirmed that the proteins constituting scMagnet (e.g., pMag and nMag) may be linked by a peptide linker, and that this linker may be a protein. Furthermore, it was confirmed that one or several amino acid residues at the linking end of each protein may be deleted. As described above, the scMagnet system developed by the present inventors is an innovative system that functions very efficiently even in environments where conventional Magnet systems did not function well, and can be used for various purposes when combined with proteins other than Magnet, such as fluorescent proteins. The present invention was completed based on the above findings.
[0012] That is, the present invention relates to the following (1) to (9): (1) A protein in which the C-terminus of the protein (a) below is linked directly or indirectly to the N-terminus of the protein (b): (a) A protein comprising an amino acid sequence having 80% or more sequence identity with an amino acid sequence obtained by deleting X consecutive amino acid residues from the C-terminal residue toward the N-terminus of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36, wherein X is an integer of 0 or more and 6 or less; (b) A protein comprising an amino acid sequence having 80% or more sequence identity with an amino acid sequence obtained by deleting Y consecutive amino acid residues from the N-terminal residue toward the C-terminus of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36, wherein Y is an integer of 0 or more and 55 or less; provided that when X of the protein (a) is 0, Y of the protein (b) is an integer of 1 or more and 55 or less, and when Y of the protein (b) is 0, X of the protein (a) is an integer of 1 or more and 6 or less. (2) The protein according to (1), wherein, in the amino acid sequence of the protein (a), the amino acids corresponding to positions 52 and 55 in the amino acid sequence represented by SEQ ID NO: 1 are substituted with arginine, or the amino acids corresponding to positions 16 and 19 in the amino acid sequence represented by SEQ ID NO: 36 are substituted with arginine, and in the amino acid sequence of the protein (b), the amino acid corresponding to position 52 in the amino acid sequence represented by SEQ ID NO: 1 is substituted with aspartic acid and the amino acid corresponding to position 55 is substituted with glycine, or the amino acid corresponding to position 16 in the amino acid sequence represented by SEQ ID NO: 36 is substituted with aspartic acid and the amino acid corresponding to position 19 is substituted with glycine. (3) The protein according to (1), wherein the C-terminus of the protein (a) and the N-terminus of the protein (b) are linked via a polypeptide. (4) The protein according to (3), wherein the polypeptide is a fluorescent protein or a bioluminescent protein.(5) The protein according to (4) above, wherein the fluorescent protein is any one of BFP, TagBFP, mTagBFP2, mBlueberry2, mCerulean, mTurquoise, ECFP, TagCFP, Rosmarius, meleCFP, mTFP1, KCY, meffCFP, GFP, YFP, Venus, mCherry, and iRFP. (6) The protein according to (4) above, wherein the bioluminescent protein is any one of NanoLu, Gaussia luciferase, Renilla luciferase, and firefly luciferase. (7) A nucleic acid encoding the protein according to any one of (1) to (6) above. (8) A method for controlling the distance between two proteins, the method comprising the steps of: binding the protein (a) to one of the two proteins described in any of (1) to (6) above; binding the protein (b) to the other of the two proteins; and irradiating the protein described in any of (1) to (6) above with light. (9) The method according to (8) above, wherein the two proteins are proteins that interact with each other. In this specification, the symbol "to" indicates a numerical range including the values on both sides of the symbol.
[0013] The photoswitching proteins of the present invention enable highly efficient control of protein binding and dissociation in environments where conventional photoswitching proteins do not function. Furthermore, the photoswitching proteins of the present invention can be used for a variety of purposes, including the functions of other proteins (e.g., fluorescent proteins) in addition to protein binding and dissociation.
[0014] Figure 1 illustrates the mechanism of action of scMagnet. (a) The three-dimensional structure of scMagnet in the dark is shown. The N-terminus of pMag and the C-terminus of nMag are at least 6 nm apart. (b) The three-dimensional structure of scMagnet under light irradiation is shown. The N-terminus of pMag and the C-terminus of nMag are located within 1 nm of each other. (c) A schematic diagram of the switching mode of scMagnet, which changes from an open to a closed conformation upon blue light irradiation. Figure 2 compares the activity of scMagnet (single-molecule system) and Magnet (two-molecule system). (a) An overview of the mechanism of action of PA-Cas9 (two-molecule system). In the dark, PA-Cas9 is split into two fragments that do not have catalytic activity against the target genomic region. Upon blue light irradiation, pMag and nMag dimerize in a light-dependent manner, inducing binding of the N- and C-terminal fragments of the split Cas9. As a result, the PA-Cas9 structure is complemented, its activity is restored, and double-strand breaks are introduced into genomic DNA. (b) The frequency (%) of light-induced indel mutations catalyzed by PA-Cas9 at the human VEGFA locus in HEK293T cells is shown. 24 hours after seeding, cells were transfected with PA-Cas9 and gRNA and incubated in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2After 24 hours of incubation in a 500-kDa atmosphere, genomic DNA was harvested from the cells. The indel mutation rates of the harvested DNA samples were measured using the TIDE assay. Data are mean ± SD (n = 3, from three independent experiments). Dots represent independent data points. Full-length Cas9 and pcDNA3.1-V5-HisA (empty vector) are positive and negative controls, respectively. In each graph for full-length Cas9, empty vector, and PA-Cas9, the left bar represents the value in the dark, and the right bar represents the value under light irradiation. (c) An overview of the mechanism of action of scPA-Cas9 (single-molecule system). In the dark, scPA-Cas9 exists as a single polypeptide, and the N- and C-terminal fragments of the split Cas9 are located separately, so they do not have catalytic activity against the target genomic region. Irradiation with blue light induces a large light-dependent conformational change in the single-strand-based magnet system (scMagnet), inducing binding between the N- and C-terminal fragments of split Cas9. This results in the PA-Ca9 structure being complemented, restoring its activity and introducing a double-strand break into genomic DNA. (d) The frequency (%) of light-induced indel mutations at the human VEGFA locus in HeLa cells catalyzed by scPA-Cas9 or PA-Cas9. Twenty-four hours after seeding, cells were transfected with scPA-Cas9 or PA-Cas9 and gRNA and incubated in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m). -2After 48 hours of incubation at 47°C, genomic DNA was harvested from the cells. The indel mutation rates of the harvested DNA samples were measured using the TIDE assay. Data are mean ± SD (n = 3, from three independent experiments). Dots represent independent data points. Full-length Cas9 and pcDNA3.1-V5-HisA (empty vector) are positive and negative controls, respectively. In each graph for full-length Cas9, empty vector, PA-Cas9, and scPA-Cas9, the left bar represents the value in the dark, and the right bar represents the value under light illumination. Figure 3 describes the structure of scPA-Cas9 and its construction constructs. (a) A schematic diagram of scPA-Cas9 is shown based on the crystal structure of Cas9, gRNA, and target DNA (PDB: 4UN3) and the crystal structure of the dimer of Vivid, the precursor protein of the magnet system (pMag and nMag), under light illumination (PDB: 3RH8). (b) A schematic diagram of the PA-Cas9 expression construct is shown. CMV (cytomegalovirus promoter) indicates the cytomegalovirus promoter, and NLS (nuclear localization signal) indicates the nuclear localization signal. (c) A schematic diagram of the scPA-Cas9 expression construct is shown. Figure 4 shows the expression constructs and their nucleotide sequences of the gRNA expression vectors. gRNAs targeting human VEGFA, human DNMT1, human EMX1, and mouse K-ras were constructed by annealed oligo cloning using the BstI site of the pU6-gRNA expression vector (Addgene: 47108). Figure 5 shows the indel mutation rates introduced into the human DNMT1 and human EMX1 loci in HEK293T cells by PA-Cas9. Twenty-four hours after cell seeding, PA-Cas9 and gRNA were transfected and incubated in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. The indel mutation rates of genomic DNA recovered from the cells were measured using the TIDE assay. Data are mean ± SD (n = 3, from three independent experiments). Dots represent independent data points. Full-length Cas9 and pcDNA3.1-V5-HisA (empty vector) are positive and negative controls, respectively. In each graph for PA-Cas9, empty vector, and full-length Cas9, the left bar represents the value in the dark, and the right bar represents the value under light irradiation. Figure 6 shows the indel mutation rates introduced into the human DNMT1 and human EMX1 loci in HeLa cells by scPA-Cas9 and PA-Cas9. Twenty-four hours after seeding, cells were transfected with scPA-Cas9 or PA-Cas9 and gRNA and incubated in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 48 hours. The indel mutation rate of genomic DNA recovered from the cells was measured using the TIDE assay. Data are means ± SD (n = 3, from three independent experiments). Dots represent independent data points. Full-length Cas9 and pcDNA3.1-V5-HisA (empty vector) are positive and negative controls, respectively. In each graph for scPA-Cas9, PA-Cas9, empty vector, and full-length Cas9, the left bar represents the value in the dark, and the right bar represents the value in light. Figure 7 demonstrates the versatility of the scMagnet system. (a) Overview of the mechanism of action of scPA-Cre. Activated by blue light, scPA-Cre induces recombination of DNA sequences flanked by two loxP sites. CMV (cytomegalovirus promoter) represents the cytomegalovirus promoter, stop represents the polyadenylation transcription "stop" signal sequence, and Fluc represents firefly luciferase. (b) Comparison of scPA-Cre (single-molecule system) and PA-Cre (two-molecule system) by luciferase assay. COS-7 cells transiently transfected with scPA-Cre or PA-Cre and a loxP-stop-loxP Fluc reporter were subjected to luciferase assay using Fluc expression as an indicator in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. The ratio of scPA-Cre-encoding DNA or PACre-encoding DNA to the total transfection amount was 4.8%. Data are means ± sd (n = 4, from three independent experiments). Dots represent independent data points. In each graph for PA-Cre and scPA-Cre, the left bar represents the value in the dark, and the right bar represents the value under light. (c) Overview of the mechanism of action of scPA-Flp. Blue-light-activated scPA-Flp induces recombination of the DNA sequence flanked by two FRT sites. (d) Comparison of scPA-Flp (single-molecule system) and PA-Flp (two-molecule system) by luciferase assay. COS-7 cells transiently transfected with scPA-Flp or PA-Flp and the FRT-stop-FRT Fluc reporter were subjected to luciferase assay using Fluc expression as an indicator in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. The ratio of scPA-Cre-encoding DNA or PA-Cre-encoding DNA to the total transfection amount was 4.8%. Data are means ± standard deviation (n = 4, from three independent experiments). Dots represent independent data points. For each graph of PA-Flp and scPA-Flp, the left bar represents the value in the dark, and the right bar represents the value under light. Figure 8 explains the structure of scPA-Cre and the construct used to create it. (a) A schematic diagram of scPA-Cre based on the crystal structure of Cre recombinase (PDB: 1CRX) and the Vivid dimer under light (PDB: 3RH8) is shown. (b) A schematic diagram of the PA-Cre expression construct is shown. CMV (cytomegalovirus promoter) represents the cytomegalovirus promoter, NLS (nuclear localization signal) represents the nuclear localization signal, and P2A represents the self-cleaving peptide. (c) A schematic diagram of the scPA-Cre expression construct is shown. Figure 9 shows the results of evaluating the activity of scPA-Cre. (a) Comparison of scPA-Cre and PA-Cre by luciferase assay. Luciferase assay using Fluc expression as an indicator in COS-7 cells transiently transfected with scPA-Cre or PA-Cre and a loxP-stop-loxP Fluc reporter was performed in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. The ratio of scPA-Cre- or PA-Cre-encoding DNA to the total transfection amount was 9.1%. Data are means ± sd (n = 12, from three independent experiments). Dots represent independent data points. Full-length Cre and pcDNA3.1 (empty vector) are positive and negative controls, respectively. In each graph for PA-Cre, scPA-Cre, empty vector, and full-length Cre, the left bar represents the value in the dark, and the right bar represents the value under light irradiation. (b) Light intensity dependence of scPA-Cre and PA-Cre. COS-7 cells transiently transfected with scPA-Cre or PA-Cre and a loxP-stop-loxP Fluc reporter were used for luciferase assays, using Fluc expression as an indicator, in the dark or under blue light irradiation (470 ± 20 nm, 0.01-3.3 W m -2 ) for 24 hours. The ratio of scPA-Cre-encoding DNA or PA-Cre-encoding DNA to the total transfection amount was 9.1%. Data are mean ± sd (n = 12, from three independent experiments). Dots represent independent data points. (c) Experimental schedule for short-term and continuous blue light irradiation. (d) Experimental schedule for different blue light irradiation times (100 W m -2 , 30 sec to 3 min; 1.0 W m -2Comparison of scPA-Cre or PA-Cre responses during incubation (30 min to 24 h). Data are mean ± SD (n = 12, from three independent experiments). Dots represent independent data points. Figure 10 illustrates the structure of scPA-Flp and the construct used to generate it. (a) Schematic diagram of scPA-Flp based on the crystal structure of Flp recombinase (PDB: 1FLO) and the Vivid dimer under light irradiation (PDB: 3RH8). (b) Schematic diagram of the PA-Flp expression construct. pMagHigh1 is the magnet for the magnet system and has high affinity and a long photocycle. CMV (cytomegalovirus promoter) and NLS (nuclear localization signal) represent the cytomegalovirus promoter and nuclear localization signal, respectively. (c) Schematic diagram of the scPA-Flp expression construct. Figure 11 shows the results of activity evaluation of scPA-Flp. (a) Comparison of scPA-Flp and PA-Flp by luciferase assay. COS-7 cells transiently transfected with scPA-Flp or PA-Flp and the FRT-stop-FRT Fluc reporter were subjected to luciferase assay using Fluc expression as an indicator in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2(b) Light intensity dependence of scPA-Flp and PA-Flp. Luciferase assays using Fluc expression as an indicator in COS-7 cells transiently transfected with scPA-Flp or PA-Flp and the FRT-stop-FRT Fluc reporter were performed in the dark or under blue light irradiation (470 ± 20 nm, 0.01–3.3 W m). -2 ) for 24 hours. Data are mean ± sd (n = 4, from three independent experiments). Dots represent independent data points. (c) Experimental schedule for short and continuous blue light irradiation. (d) Experimental schedule for different blue light irradiation times (100 W m -2 , 30 sec to 3 min; 1.0 W m -2 Comparison of the responses of scPA-Flp or PA-Flp to 30 min to 24 h. Data are mean ± SD (n = 4, from three independent experiments). Dots represent independent data points. In each graph for PA-Flp, scPA-Flp, and full-length Flp, the left bar indicates the value in the dark, and the right bar indicates the value under light. Figure 12 shows the results of evaluating the activity of scPA-Cre and scPA-Flp in NIH3T3 cells. (a) Comparison of the activity of scPA-Cre and PA-Cre by luciferase assay. NIH3T3 cells transiently transfected with scPA-Cre or PA-Cre and a loxP-stop-loxP Fluc reporter were subjected to luciferase assay using Fluc expression as an indicator in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. The ratio of scPA-Cre-encoding DNA or PA-Cre-encoding DNA to the total transfection amount was 4.8%. Data are means ± sd (n = 4, from three independent experiments). Dots represent independent data points. In each graph for PA-Cre and scPA-Cre, the left bar represents the value in the dark, and the right bar represents the value under light. (b) Comparison of scPA-Flp and PA-Flp by luciferase assay. Luciferase assay using Fluc expression as an indicator in NIH3T3 cells transiently transfected with scPA-Flp or PA-Flp and the FRT-stop-FRT Fluc reporter was performed in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2 ) for 24 hours. The ratio of scPA-Cre-encoding DNA or PA-Cre-encoding DNA to the total transfection amount was 4.8%. Data are means ± SD (n = 4, from three independent experiments). Dots represent independent data points. For PA-Flp and scPA-Flp, the left bar represents the value in the dark, and the right bar represents the value under light. Figure 13 shows the effects of amino acid deletions in the linker and pMag on the activity of scMagnet. (a) Luciferase assay results comparing the activity of directly linked scPA-Cre with that of scPA-Cre linked with linkers of various lengths. (b) Luciferase assay results comparing the activity of directly linked scPA-Cre with that of scPA-Cre mutants in which 1 to 6 amino acids were deleted from the C-terminus of pMag and linked with linkers of various lengths. Luciferase assays using Fluc expression as an indicator in COS-7 cells transiently transfected with scPA-Cre or scPA-Cre mutants and the loxP-stop-loxP Fluc reporter were performed in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. Data are mean ± SD (n=4, from three independent experiments). Dots represent independent data points. For each scPA-Cre or scPA-Cre mutant, the upper bar indicates the value in the dark, and the lower bar indicates the value under light. Figure 14 shows the results of examining the suitability of the linker for scMagnet using scPA-Cas9. (a) A flexible linker (GSGGGSGGGSGGGSGGGSGS; SEQ ID NO: 34) or a rigid linker (GSAEAAAKAGSAEAAAKAGS; SEQ ID NO: 35) was inserted between pMag and nMagHigh1. "No linker" indicates direct linkage between pMag and nMagHigh1. CMV (cytomegalovirus promoter) indicates the cytomegalovirus promoter, and NLS (nuclear localization signal) indicates the nuclear localization signal. (b) 5-11 cells (LSL-KrasG12D / +; LSL-Trp53 R172H / + Measurement of light-induced indel mutations by scPA-Cas9 and PA-Cas9 at the mouse K-ras locus in a cell line derived from pancreatic cancer of ptf1a-Cre (KPC) mice. 24 hours after seeding, cells were transfected with scPA-Cas9 or PA-Cas9 and gRNA and incubated in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 48 hours. The indel mutation rate of genomic DNA recovered from the cells was measured using the TIDE assay. Data are means ± SD (n = 3, from three independent experiments). Dots represent independent data points. Full-length Cas9 and pcDNA3.1-V5-HisA (empty vector) are positive and negative controls, respectively. In each graph, for scPA-Cas9 (flexible, rigid, and no linker), PA-Cas9, empty vector, and full-length Cas9, the left bar represents the value in the dark, and the right bar represents the value under light. Figure 15 shows the effect of amino acid deletions in nMag on the activity of scMagnet. The activity of directly linked scPA-Cre and that of a scPA-Cre mutant with 1 to 19 amino acids deleted from the N-terminus of nMag and linked to pMag were compared using a luciferase assay. Luciferase assays using Fluc expression as an indicator in COS-7 cells transiently transfected with scPA-Cre or scPA-Cre mutants and the loxP-stop-loxP Fluc reporter were performed in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. Data are means ± SD (n = 4, from three independent experiments). Dots represent independent data points. For each scPA-Cre or scPA-Cre mutant, the upper bar indicates the value in the dark, and the lower bar indicates the value in light. Figure 16 shows the results of examining the Cre recombination activity of scPA-Cre mutants introduced with nMag, which progressively deletes amino acids at the N-terminus. We created scPA-Cre mutants introduced with nMag mutants containing only Latch-NCap-Hinge, and scPA-Cre mutants introduced with nMag mutants deleted at the N-terminus by amino acid residues 119 (Δ119), 71 (Δ71), 56 (Δ56), or 35 (Δ35), and measured Cre recombination activity. Panel a shows a schematic diagram of the structure of each nMag mutant, and panel b shows the results of measuring Cre recombination activity. Luciferase assays using Fluc expression as an indicator in COS-7 cells transiently transfected with scPA-Cre (pMag+nMag) or scPA-Cre mutants and the loxP-stop-loxP Fluc reporter were performed in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours. Data are mean ± SD (n = 4, from three independent experiments). Dots represent independent data points. In the graph in (b), the upper bar represents the value in the dark, and the lower bar represents the value in light. Figure 17 shows the results of examining the Cre recombination activity of scPA-Cre mutants introduced with various combinations of mutants in which the C-terminus of pMag and the N-terminus of nMag were partially deleted and linked. We constructed various scPA-Cre mutants by linking pMag mutants with one (pMag-CtermΔ1), two (pMag-CtermΔ2), five (pMag-CtermΔ5), or six (pMag-CtermΔ6) amino acid residues deleted from the C-terminus of pMag, and nMag mutants with one (nMag-NtermΔ1), two (nMag-NtermΔ2), nine (nMag-NtermΔ9), or 19 (nMag-NtermΔ19) amino acid residues deleted from the N-terminus of nMag, and measured their Cre recombination activity. COS-7 cells were transiently transfected with scPA-Cre (pMag+nMag) or scPA-Cre mutants and the loxP-stop-loxP Fluc reporter. Luciferase assays were performed using Fluc expression as an indicator in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2 ) for 24 hours. Data are mean ± sd (n = 4, from three independent experiments). Dots represent independent data points. In the graph, the upper bar indicates the value in the dark, and the lower bar indicates the value under light irradiation. Figure 18 shows the results of evaluating the light-dependent recombination cascade combining full-length Cre and scPA-Flp. (a) Schematic of the recombination cascade using multiple gene expression stages. (b) COS-7 cells transfected with the cDNAs shown in (c) were incubated in the dark or under blue light irradiation (470 ± 20 nm, 1.0 W m -2) for 24 hours, and then a luciferase assay was performed. Data are mean ± SD (n=4, from three independent experiments). Dots represent independent data points. Full-length Cas9 and pcDNA3.1-V5-HisA (empty vector) are positive and negative controls, respectively. In each graph for empty vector and full-length Cre, the left bar represents the value in the dark, and the right bar represents the value under light irradiation. (c) Transfection conditions for the luciferase assay shown in (b) are shown. Figure 19 shows the results of evaluating the light-dependent recombination cascade in vivo, combining full-length Cre and scPA-Flp. (a) Overview of the recombination cascade with multiple gene expression steps is shown. (b) Schedule of the in vivo experiment is shown. (c) CreER T2 This shows the intracellular operation of the scPA-Flp recombination cascade initiated by Rosa26-CreER. T2 After injecting tamoxifen or corn oil into knock-in mice, the mice were transiently injected with cDNA encoding loxP-stop-loxP scPA-Flp and the FRT-stop-FRT mKate2 reporter by hydrodynamic tail vein (HTV) injection. The mice were then incubated in the dark or under blue light irradiation (470 ± 20 nm, 132 W m -2 ) for 18 hours. 18 hours after feeding, the livers were excised from the mice and fluorescent imaging was performed. The image shows a typical result obtained from three measurements. The scale bar is 1 mm. Figure 20 shows the results of evaluating scPA-Flp activity in vivo. (a) Experimental schedule. Rosa26-CreER T2Knockin mice were intraperitoneally injected with 200 μL of tamoxifen (27 mM) or corn oil. Six hours later, the mice were injected with cDNA encoding loxP-stop-loxP scPA-Flp and the FRT-stop-FRT mKate2 reporter by hydrodynamic tail vein (HTV) injection. Six hours after cDNA injection, the mice were incubated in the dark or under blue light (470 ± 20 nm, 132 W m -2) for 18 hours. Livers were removed from mice 18 hours after feeding and subjected to fluorescence imaging. (b) An image different from that shown in Figure 16c is shown. The scale bar is 1 mm. Figure 21 shows a schematic diagram of the structure and mechanism of action of scPA-Vav. (a) A schematic diagram of scPA-Vav based on the crystal structure of mouse Vav2 GEF9 and Vivid dimers (PDB: 3RH8) under light irradiation. (b) A schematic diagram of the mechanism of action of scPA-Vav in cell spreading. Vav2 is a Rho family guanine exchange factor that converts GDP to GTP and activates Rac1 GTPase in various cells. GAP stands for GTPase-activating protein, and PAK stands for p21-associated kinase. Figure 22 shows the results of an investigation into the reversibility of scMagnet function. (a) A schematic diagram of scPA-Vav under blue light (BL) irradiation. (b) Schematic diagram of the scPA-Vav construct. In the cell area spreading assay, Lifeact-mCherry was used as a biosensor to detect actin polymerization. P2A represents the self-cleaving peptide. (c) Assay results for light-dependent cell area spreading activity induced by scPA-Vav. Fluorescence images of NIH 3T3 cells expressing Lifeact-mCherry and scPA-Vav2 were taken 15 minutes before, during, and 15 minutes after blue light irradiation. Blue light irradiation was performed with a 488 nm, 1 mW laser. A binary image of the cells is shown on the right. Representative results from four independent experiments are shown. (d) Quantification of the cell spreading area of scPA-Vav2-expressing cells. Data are plotted for independent data points (n = 4, from four independent experiments). (e) Quantification of the cell spreading area of scPA-Vav2-expressing cells in the presence of EHop-016 (a Rac GTPase inhibitor, 1 μM). Data are plotted from independent data values (n=4, from four independent experiments). (f) Schematic illustrating that EHop-016 inhibits the binding of Rac1 to the Rho GEF Vav2. (g) Kymograph of the cell area along the line indicated in the left panel. Results are shown as representative experiments selected from four independent experiments. ***P < 0.001 by Welch's two-tailed t-test.ns indicates no significant difference. Scale bar: 10 μm. Figure 23 shows the results of quantifying the amount of cell spreading induced by scPA-Vav and 2PscPA-Vav. Fluorescence images of NIH 3T3 cells expressing Lifeact-mCherry and scPA-Vav or 2PscPA-Vav were acquired 15 minutes before blue light irradiation (dark), during blue light irradiation (before), and 15 minutes after blue light irradiation (after). Blue light irradiation was performed with a 488 nm, 1 mW laser for one-photon excitation experiments and an 808 nm, 25 mW laser for two-photon excitation experiments. Binary images of the cells are shown on the right. Typical results from four independent experiments are shown. Fluorescence images were converted to binary data using ImageJ software. The binary data were used to calculate the ratio of the "dark" cell area to the "before" cell area and the ratio of the "before" cell area to the "after" cell area. Figure 24 shows the analysis results of light-dependent cell area expansion induced by scPA-Vav. Fluorescence images of NIH 3T3 cells expressing Lifeact-mCherry and scPA-Vav were acquired 15 minutes before, during, and 15 minutes after blue light irradiation. Blue light irradiation was performed with a 488 nm, 1 mW laser. Fluorescence images were converted to binary data using ImageJ software. The binary data were used to calculate the ratio of the cell area before irradiation to the cell area in the dark (dark) and the ratio of the cell area after irradiation to the cell area before irradiation (BL). The calculated cell expansion rates were used to create the graphs in Figures 22d and 22e. All scale bars are 10 μm. Figure 25 shows the results of an investigation into the operation of the scMagnet system using two-photon excitation. (a) A schematic diagram of the mechanism of action of 2PscMagnet. mTagBFP2 was inserted between pMag and nMag (2PscMagnet).2PscMagnet can be activated by two-photon excitation via fluorescence resonance energy transfer (FRET) from mTagBPF2 to flavin adenine dinucleotide (FAD) bound to pMag and nMag. (b) The three-dimensional structure of 2PscMagnet is shown. The distances between the chromophore of mTagBFP2 (FRET donor) and the FAD of pMag (FRET acceptor) and the FAD of nMag (FRET acceptor) are approximately 3 nm and 4 nm, respectively. These distances are sufficiently close for FRET to occur. (c) A schematic diagram of the structure of 2PscPA-Vav. Based on the crystal structure information, the N-terminal amino acid residues (aa 1-6) and C-terminal amino acid residues (aa 229-237) of mTagBPF2 were maximally shortened and inserted into scMagnet. (d) Quantification of the spreading area of 2PscPA-Vav-expressing cells after one-photon excitation. Light-dependent cell area extension was induced by irradiating the cells with 488 nm, 1 mW laser light. Data are plotted as independent data (n = 4, from four independent experiments). (e) Light-dependent cell area extension was induced by two-photon (2P) excitation of 2PsPA-Vav. Fluorescence images of NIH 3T3 cells expressing Lifeact-mCherry and 2PscPA-Vav2 were acquired 15 minutes before, during, and 15 minutes after two-photon excitation. Two-photon excitation was performed with an 808 nm, 25 mW laser. A binary image of the cells is shown on the right. Typical results from four independent experiments are shown. (f and g) Quantification of the spreading area of cells expressing 2PscPA-Vav2 (f) or scPA-Vav2 (g). Light-dependent cell area expansion was induced by 2PsPA-Vav or scPA-Vav2 using 808 nm, 25 mW laser light. Data are plotted as independent data (n = 4, from four independent experiments). ***P < 0.001 by Welch's two-tailed t-test. ns indicates no significant difference. The scale bar is 10 μm. Figure 26 shows the results of an analysis of light-dependent cell area expansion induced by 2PscPA-Vav.Fluorescence images of NIH 3T3 cells expressing Lifeact-mCherry and 2P scPA-Vav were acquired 15 minutes before (dark), during (before), and 15 minutes after (after) light exposure. Light exposure was performed using a 488 nm, 1 mW laser for one-photon excitation (a) and an 808 nm, 25 mW laser for two-photon excitation (b). Fluorescence images were converted to binary data using ImageJ software. The binary data were used to calculate the ratio of the "dark" cell area to the "before" cell area and the ratio of the "before" cell area to the "after" cell area. The calculated cell spreading ratios were used to generate the graphs in Figures 25d and 25f. All scale bars are 10 μm. Figure 27 shows the analysis of light-dependent cell spreading induced by scPA-Vav. Fluorescence images of NIH 3T3 cells expressing Lifeact-mCherry and scPA-Vav were taken 15 minutes before (dark), during (before), and 15 minutes after (after) light exposure. Light exposure was performed with an 808 nm, 25 mW laser. Fluorescence images were converted to binary data using ImageJ software. The binary data was used to calculate the ratio of the "dark" cell area to the "before" cell area and the ratio of the "before" cell area to the "after" cell area. The calculated cell spreading ratios were used to create the graph in Figure 25g. All scale bars are 10 μm. Figure 28 shows the nucleotide sequence of pcDNA3.1-V5-HisA-PA-Cas9_N-term (SEQ ID NO: 18). Figure 29 shows the nucleotide sequence of pcDNA3.1-V5-HisA-PA-Cas9_C-term (SEQ ID NO: 19). Figure 30 shows the nucleotide sequence of pcDNA3.1-V5-HisA-scPA-Cas9 (flexible linker) (SEQ ID NO: 20), Figure 31 shows the nucleotide sequence of pcDNA3.1-V5-HisA-scPA-Cas9 (rigid linker) (SEQ ID NO: 21), and Figure 32 shows the nucleotide sequence of pcDNA3.1-V5-HisA-scPA-Cas9 (direct linkage) (SEQ ID NO: 22).Figure 33 shows the nucleotide sequence of pcDNA3.1-PA-Cre (SEQ ID NO: 23). Figure 34 shows the nucleotide sequence of pcDNA3.1-scPA-Cre (SEQ ID NO: 24). Figure 35 shows the nucleotide sequence of pcDNA3.1-loxP-stop-loxP-Fluc (SEQ ID NO: 25). Figure 36 shows the nucleotide sequence of pcDNA3.1-PA-Flp_N-term (SEQ ID NO: 26). Figure 37 shows the nucleotide sequence of pcDNA3.1-PA-Flp_C-term (SEQ ID NO: 27). Figure 38 shows the nucleotide sequence of pcDNA3.1-scPA-Flp (SEQ ID NO: 28). Figure 39 shows the nucleotide sequence of pcDNA3.1-FRT-stop-FRT-Fluc (SEQ ID NO: 29). Figure 40 shows the nucleotide sequence of pcDNA3.1-FRT-stop-FRT-Akaluc-mKate2 (SEQ ID NO: 30). Figure 41 shows the nucleotide sequence of pcDNA3.1-loxP-stop-loxP-scPA-Flp (SEQ ID NO:31). Figure 42 shows the nucleotide sequence of pEF6-Lifeact-mCherry-P2A-scPA-Vav (SEQ ID NO:32). Figure 43 shows the nucleotide sequence of pEF6-Lifeact-mCherry-P2A-2PscPA-Vav (SEQ ID NO:33).
[0015] Modes for carrying out the present invention are described below. The term "present embodiment" refers to all embodiments described herein unless otherwise specified. The first embodiment is an optical switch protein, which is composed of a single polypeptide, unlike conventional optical switch proteins composed of two separate proteins. The "optical switch protein" according to this embodiment is a protein in which two proteins selected from VVD or a VVD mutant (hereinafter, unless otherwise specified, the term "VVD protein" refers to VVD or a VVD mutant) are directly linked or indirectly linked via a linker of one amino acid residue or peptide. In some cases, the VVD protein may lack one or more consecutive amino acid residues from the amino acid residue at the end linked to the other VVD protein toward the opposite end. For example, when the optical switch protein according to this embodiment comprises a wild-type VVD and a VVD mutant (referred to as VVD1) linked by a polypeptide linker L (Nter-VVD-L-VVD1-Cter), one or more consecutive amino acid residues may be deleted from the C-terminal residue of the wild-type VVD toward the N-terminal side, and / or one or more consecutive amino acid residues may be deleted from the N-terminal residue of VVD1 toward the C-terminal side. Here, in the deletion of "one or more" amino acid residues, "multiple" refers to, for example, 2 to 30, preferably 2 to 20, and more preferably 2 to 10. In the optical switch protein according to this embodiment, the leak activity of the optical switch protein in the dark can be reduced by deleting amino acid residues in the terminal region of the VVD protein that binds to the linker as described above.
[0016] When the two VVD proteins constituting the optical switch protein according to this embodiment are indirectly linked, the two VVD proteins may be linked via a linker consisting of one amino acid residue or a peptide. When the linker is a peptide, the linker may be an oligopeptide (e.g., approximately 10 or less amino acids), a polypeptide (e.g., approximately 10 to 100, 10 to 50, or 10 to 30 amino acids), a protein, or the like. When the linker is an oligopeptide or polypeptide that does not have a specific structure, the amino acids constituting the linker include, but are not limited to, glycine (G), serine (S), alanine (A), and threonine (T). In the case of proteins, the proteins are not particularly limited, and may include, for example, fluorescent proteins (e.g., BFP, TagBFP, mTagBFP2, mBlueberry2, mCerulean, mTurquoise, ECFP, TagCFP, Rosmarius, meleCFP, mTFP1, KCY, meffCFP, GFP, YFP, Venus, mCherry, and iRFP) and bioluminescent proteins (e.g., NanoLuc, Gaussia luciferase, Renilla luciferase, and firefly luciferase).
[0017] The photoswitch protein according to this embodiment undergoes a significant structural change upon light irradiation, resulting in the VVD proteins present on both sides of the linker binding to each other and dissociating in the dark (when not irradiated with light). When two interacting proteins are linked to each of the two VVD proteins constituting the photoswitch protein according to this embodiment (i.e., the N- and C-termini of the photoswitch protein), the photoswitch protein can bring the two proteins into proximity and enable interaction by irradiating them with light, and the two fragments can be dissociated by terminating the light irradiation. Here, the "two interacting proteins" may be two protein fragments obtained by cleaving a single protein. Therefore, for example, when fragments of a protein are bound to the N- and C-termini of the photoswitch protein according to this embodiment, the rebinding and dissociation of the fragments can be controlled by turning light irradiation on and off, thereby controlling the activity of the protein (the protein before cleavage).
[0018] As described above, the VVD protein of this embodiment includes wild-type VVD (SEQ ID NO: 1) and its mutants, and may include the VVD mutants described below, as well as a VVD mutant (SEQ ID NO: 36) in which the first to 36 amino acid residues of the wild-type VVD consisting of the amino acid sequence represented by SEQ ID NO: 1 are deleted. It has been reported that deleting the 36 amino acid residues on the N-terminus of VVD improves its expression level (Zoltowski et al., Biochemistry 47:7012-7019 2008). Therefore, the VVD protein of this embodiment may be a protein in which the amino acid mutations described below have been appropriately introduced into a VVD protein consisting of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36.
[0019] More specifically, the optical switch protein according to this embodiment is a protein in which the C-terminus of the following protein (a) is directly or indirectly linked to the N-terminus of the following protein (b): (a) a protein comprising an amino acid sequence having 80% or greater sequence identity with an amino acid sequence in which X consecutive amino acid residues from the C-terminal residue to the N-terminal side of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36 are deleted, where X is an integer between 0 and 6; or (b) a protein comprising an amino acid sequence having 80% or greater sequence identity with an amino acid sequence in which Y consecutive amino acid residues from the N-terminal residue to the C-terminal side of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36 are deleted, where Y is an integer between 0 and 30. Here, the protein consisting of the amino acid sequence represented by SEQ ID NO: 1 below is Vivid (VVD) derived from Neurospora Crassa, and the protein consisting of the amino acid sequence represented by SEQ ID NO: 36 is a VVD mutant consisting of the amino acid sequence represented by SEQ ID NO: 1 with the 1st to 36th amino acids deleted. SEQ ID NO: 1: MSHTVNSSTMNPWEVEAYQQYHYDPRTAPTANPLFFHTLYAPGGYDIMGYLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE SEQ ID NO: 36: HTLYAPGGYDIMGYLIQIMNRPNPQVELGPVDTSCALILCDLKQKDTPIVYASEAFLYMTGYSNAEVLGRNCRFLQSPDGMVKPKSTRKYVDSNTINTMRKAIDRNAEVQVEVVNFKKNGQRFVNFLTMIPVRDETGEYRYSMGFQCETE
[0020] In the "amino acid sequence having X contiguous amino acid residues deleted from the C-terminal residue toward the N-terminal of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36," for example, when X is 0, the sequence refers to a sequence in which no amino acids are deleted from the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36. Furthermore, when X is 20, the sequence refers to an amino acid sequence in which 20 contiguous amino acid residues deleted from the C-terminal residue toward the N-terminal of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36. More specifically, for example, "an amino acid sequence having 20 contiguous amino acid residues deleted from the C-terminal residue toward the N-terminal of the amino acid sequence represented by SEQ ID NO: 1" refers to a sequence consisting of contiguous amino acid residues from the 1st amino acid residue to the 166th amino acid residue in the amino acid sequence represented by SEQ ID NO: 1. Here, X is an integer of 0 to 30, preferably an integer of 0 to 20, more preferably an integer of 0 to 15, and even more preferably an integer of 0 to 6.
[0021] In the "amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36, Y contiguous amino acid residues from the N-terminal residue to the C-terminal side" sequence, for example, when Y is 0, the sequence refers to a sequence in which no amino acids are deleted from the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36. Furthermore, when Y is 20, the sequence refers to an amino acid sequence in which 20 contiguous amino acid residues from the N-terminal residue to the C-terminal side of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36 are deleted. More specifically, for example, "an amino acid sequence represented by SEQ ID NO: 1, 20 contiguous amino acid residues from the N-terminal residue to the C-terminal side of the amino acid sequence represented by SEQ ID NO: 1" refers to a sequence consisting of contiguous amino acid residues from the 21st amino acid residue to the 186th amino acid residue in the amino acid sequence represented by SEQ ID NO: 1. Here, Y is an integer of 0 to 70, preferably an integer of 0 to 60, more preferably an integer of 0 to 55, and even more preferably an integer of 0 to 35.
[0022] In the above protein (a) and protein (b) constituting the optical switch protein according to this embodiment, when X of protein (a) is 0, Y of protein (b) may be an integer of 1 or more and 30 or less, and when Y of protein (b) is 0, X of protein (a) may be an integer of 1 or more and 30 or less. That is, at least one of protein (a) and protein (b) constituting the optical switch protein according to this embodiment may have a deletion of 1 or more and 30 or less amino acid residues at the linking end (i.e., the end bonded to the other VVD protein or the linker).
[0023] In this embodiment, a "protein having 80% or more sequence identity" refers to a protein having 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, or 99% or more sequence identity to an "amino acid sequence having X consecutive amino acid residues deleted from the C-terminal residue to the N-terminal side of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36" or an "amino acid sequence having Y consecutive amino acid residues deleted from the N-terminal residue to the C-terminal side of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36." Here, proteins other than those having 100% sequence identity among "proteins having 80% or more sequence identity" are mutants of the protein consisting of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36. The VVD mutant that constitutes the optical switch protein of this embodiment is not particularly limited, as long as it has the property of binding to other VVD proteins that constitute the optical switch protein of this embodiment upon light irradiation and of the binding being broken (dissociated) in the dark; for example, the VVD mutants described below are desirable.
[0024] Desirable mutants include, for example, mutants disclosed in Patent Document 1. When the photoswitch proteins of this embodiment, i.e., the proteins belonging to either (a) or (b) above, are VVD mutants, it is desirable that in one VVD mutant (referred to as "VVD mutant 1"), at least one amino acid located on the binding surface with the other VVD mutant (referred to as "VVD mutant 2") is substituted from an amino acid contained in wild-type VVD with an amino acid having a positive charge in the side chain, and that in VVD mutant 2, at least one amino acid located on the binding surface with VVD mutant 1 is substituted with an amino acid having a negative charge in the side chain. Such VVD mutants have high binding affinity to each other.
[0025] In this specification, the term "amino acid" is used in the broadest sense and includes not only natural amino acids but also their derivatives and artificial amino acids. In this specification, the term "amino acid" includes, for example, natural amino acids as well as unnatural amino acids. Furthermore, the term "amino acid" also includes amino acids whose main chain structure differs from that of natural amino acids, amino acids whose side chain structure differs from that of natural amino acids, amino acids having an extra methylene in the side chain, and amino acids in which the carboxylic acid functional group in the side chain is replaced with a sulfonic acid group. The amino acids having a positive charge in the side chain may be natural or unnatural amino acids, with natural amino acids including lysine, arginine, and histidine. The amino acids having a negative charge in the side chain may be natural or unnatural amino acids, with natural amino acids including aspartic acid and glutamic acid.
[0026] In at least one of the VVD mutants constituting the optical switch protein according to this embodiment, at least one amino acid located in the flavin adenine dinucleotide (FAD)-binding domain (FAD-binding domain) of the cofactor may be substituted. The FAD-binding domain can be appropriately determined by those skilled in the art through protein crystallography or other methods. One or more amino acids in the FAD-binding domain may be substituted. The number of substituted amino acids is not particularly limited, and may be, for example, 1, 2, 3, 4, 5, 6, 7, 8, or 9. Furthermore, the amino acids in the FAD-binding domain may be substituted with any amino acid, as long as the binding and dissociation between the VVD or VVD mutant constituting the optical switch protein occurs at the desired rate.
[0027] The VVD mutant according to this embodiment will be described in more detail. As used herein, when specifying the position of the amino acid sequence of a VVD mutant, "the amino acid corresponding to the Zth position in the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36" refers to the amino acid in the amino acid sequence of the VVD mutant that corresponds to the Zth position in the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36 when the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36 and the amino acid sequence of the VVD mutant are aligned to maximize the degree of identity.
[0028] When the optical switch protein according to this embodiment includes VVD mutant 1 and VVD mutant 2, for example, in VVD mutant 1, the amino acid corresponding to the 52nd amino acid in the amino acid sequence represented by SEQ ID NO: 1 may be an amino acid having a positive charge in its side chain, and in VVD mutant 2, the amino acid corresponding to the 52nd amino acid in the amino acid sequence represented by SEQ ID NO: 1 may be an amino acid having a negative charge in its side chain. Alternatively, in VVD mutant 1, the amino acid corresponding to the 16th amino acid in the amino acid sequence represented by SEQ ID NO: 36 may be an amino acid having a positive charge in its side chain, and in VVD mutant 2, the amino acid corresponding to the 16th amino acid in the amino acid sequence represented by SEQ ID NO: 36 may be an amino acid having a negative charge in its side chain. Note that when the two VVD proteins used in this embodiment are a combination of mutants, they may be a combination of a mutant consisting of an amino acid sequence in which a mutation has been introduced into the amino acid sequence represented by SEQ ID NO: 1 and a mutant consisting of an amino acid sequence in which a mutation has been introduced into the amino acid sequence represented by SEQ ID NO: 36 (the same applies to the combinations of mutants described below).
[0029] When the optical switch protein according to this embodiment includes VVD mutant 1 and VVD mutant 2, for example, in VVD mutant 1, the amino acid corresponding to the 55th amino acid in the amino acid sequence represented by SEQ ID NO: 1 may be an amino acid having a positive charge in its side chain, and in VVD mutant 2, the amino acid corresponding to the 55th amino acid in the amino acid sequence represented by SEQ ID NO: 1 may be an amino acid having a negative charge in its side chain. Alternatively, in VVD mutant 1, the amino acid corresponding to the 19th amino acid in the amino acid sequence represented by SEQ ID NO: 36 may be an amino acid having a positive charge in its side chain, and in VVD mutant 2, the amino acid corresponding to the 19th amino acid in the amino acid sequence represented by SEQ ID NO: 36 may be an amino acid having a negative charge in its side chain.
[0030] When the optical switch protein according to this embodiment includes VVD mutant 1 and VVD mutant 2, for example, in VVD mutant 1, the amino acids corresponding to the 52nd and 55th amino acids in the amino acid sequence represented by SEQ ID NO: 1 may be arginine, and in VVD mutant 2, the amino acid corresponding to the 52nd amino acid in the amino acid sequence represented by SEQ ID NO: 1 may be aspartic acid and the amino acid corresponding to the 55th amino acid may be glycine. Alternatively, in VVD mutant 1, the amino acids corresponding to the 16th and 19th amino acids in the amino acid sequence represented by SEQ ID NO: 36 may be arginine, and in VVD mutant 2, the amino acid corresponding to the 16th amino acid in the amino acid sequence represented by SEQ ID NO: 36 may be aspartic acid and the amino acid corresponding to the 19th amino acid may be glycine.
[0031] When the light switch protein according to this embodiment includes VVD variant 1 and VVD variant 2, the amino acid located in the FAD-binding domain of at least one of the variants may be an amino acid different from the wild-type amino acid. For example, in at least either VVD variant 1 or VVD variant 2, the amino acids corresponding to positions 74 and / or 85 in the amino acid sequence represented by SEQ ID NO: 1 may be amino acids different from the amino acids in the amino acid sequence represented by SEQ ID NO: 1. Alternatively, in at least either VVD variant 1 or VVD variant 2, the amino acids corresponding to positions 135 and / or 165 in the amino acid sequence represented by SEQ ID NO: 1 may be amino acids different from the amino acids in the amino acid sequence represented by SEQ ID NO: 1. Alternatively, in at least either VVD variant 1 or VVD2 variant, the amino acids corresponding to positions 38 and / or 49 in the amino acid sequence represented by SEQ ID NO: 36 may be amino acids different from the amino acids in the amino acid sequence represented by SEQ ID NO: 36. Alternatively, in at least either VVD variant 1 or VVD variant 2, the amino acids corresponding to the 99th and / or 129th positions on the amino acid sequence represented by SEQ ID NO: 36 may be different from the amino acids in the amino acid sequence represented by SEQ ID NO: 36.
[0032] More specifically, when the optical switch protein according to this embodiment includes VVD variant 1 and VVD variant 2, for example, in VVD variant 1 and VVD variant 2, the amino acid corresponding to the 85th position in the amino acid sequence represented by SEQ ID NO: 1 may be valine, or the amino acids corresponding to the 74th and 85th positions in the amino acid sequence represented by SEQ ID NO: 1 may both be valine. Alternatively, when the optical switch protein according to this embodiment includes VVD variant 1 and VVD variant 2, for example, in VVD variant 1 and VVD variant 2, the amino acids corresponding to the 135th and 165th positions in the amino acid sequence represented by SEQ ID NO: 1 may both be isoleucine. Alternatively, when the optical switch protein according to this embodiment includes VVD variant 1 and VVD variant 2, for example, in VVD variant 1 and VVD variant 2, the amino acid corresponding to the 49th position in the amino acid sequence represented by SEQ ID NO: 36 may be valine, or the amino acids corresponding to the 38th and 49th positions in the amino acid sequence represented by SEQ ID NO: 1 may both be valine. Alternatively, when the optical switch protein of this embodiment includes VVD mutant 1 and VVD mutant 2, for example, in VVD mutant 1 and VVD mutant 2, the amino acids corresponding to the 99th and 129th positions in the amino acid sequence represented by sequence number 36 may both be isoleucine.
[0033] The two VVD proteins constituting the optical switch protein according to this embodiment may each be bound to or fused with an "another substance (i.e., a substance different from each protein constituting the optical switch protein)." The "another substance" is not particularly limited and may be any substance, including various biological substances such as proteins, lipids, sugars, and nucleic acids. The optical switch protein according to this embodiment and the "another substance" may be bound via a linker or the like. If the "another substance" is a protein, it may be fused to the protein. More specifically, examples of the "another substance" include interacting "protein A" and "protein B," such as the "Cas9 Nter" and "Cas9 Cter" shown in FIG. 2c, the "CreN" and "CreC" shown in FIG. 7a, the "FlpN" and "FlpC" shown in FIG. 7c, and the "mVav2 N-ter" and "mVav2 C-ter" shown in FIG. 22a. In this case, when the photoswitch protein according to this embodiment is irradiated with blue light (for example, in a wavelength region, although not particularly limited, of about 400 nm to 500 nm), an interaction between protein A and protein B can be induced, and when the irradiation of blue light is stopped, protein A and protein B can be dissociated. Therefore, by using the photoswitch protein according to this embodiment, it is possible to freely control the interaction between proteins by turning light irradiation on and off. In addition to the examples shown here, the photoswitch protein according to this embodiment has other useful applications (see, for example, Non-Patent Document 1 and Non-Patent Document 2).
[0034] The second embodiment is a nucleic acid (DNA or RNA) encoding the optical switch protein according to this embodiment. The nucleic acid according to this embodiment can be prepared by a method known in the art or a method obtained by appropriately modifying the method. For example, the desired nucleic acid may be obtained by introducing a desired mutation into DNA encoding wild-type VVD. Alternatively, the nucleic acid can be synthesized using an automated synthesizer. When each protein constituting the optical switch according to this embodiment is fused with another protein, the nucleic acid encoding such a fusion protein is also included in the nucleic acid according to this embodiment.
[0035] The photoswitch proteins according to this embodiment can be prepared by inserting a nucleic acid encoding the protein into an appropriate expression vector, transforming or transfecting appropriate host cells with the expression vector, culturing the cells in an appropriate medium, and purifying the expressed proteins. Examples of host cells for protein expression include bacterial cells (e.g., Escherichia coli B strain, E. coli K12 strain, Corynebacterium ammoniagenes, C. glutamicum, Serratia liquefaciens, Streptomyces lividans, Pseudomonas putida, etc.), fungi (e.g., Penicillium camembertii, Acremonium chrysogenum, etc.), animal cells, plant cells, baculovirus / insect cells, or yeast cells (e.g., Saccharomyces cerevisiae and Pichia pastoris, etc.).
[0036] Protein expression vectors suitable for various host cells can be used. Examples of suitable expression vectors include pBR322, pBR325, pUC118, and pET (E. coli hosts), pEGFP-C and pEGFP-N (animal host cells), pVL1392 and pVL1393 (insect host cells, baculovirus vectors), and pG-1, Yep13, and pPICZ (yeast host cells). These expression vectors contain an origin of replication, a selection marker, and a promoter appropriate for each vector, and may optionally contain an enhancer, a transcription termination sequence (terminator), a ribosome binding site, and a polyadenylation signal. Furthermore, to facilitate purification of the expressed polypeptide, the expression vector may contain a nucleotide sequence for fusion expression of a FLAG tag, His tag, HA tag, or GST tag. Expression vectors can be constructed using techniques known to those skilled in the art, or, if appropriate, using commercially available kits.
[0037] When extracting an expressed protein from cultured bacterial cells or cultured cells, the bacterial cells or cultured cells are collected after cultivation using a known method, suspended in an appropriate buffer, and disrupted by ultrasound, lysozyme, and / or freeze-thawing, followed by centrifugation or filtration to obtain a soluble extract. In particular, when cultured cells are used as hosts, it is preferable to obtain the protein expressed in the culture supernatant by recovering the supernatant. The target protein can be obtained from the resulting extract or culture supernatant by appropriately combining known separation and purification methods. Known separation and purification methods include methods that utilize solubility, such as salting out and solvent precipitation; methods that mainly utilize differences in molecular weight, such as dialysis, ultrafiltration, gel filtration, and SDS-PAGE; methods that utilize differences in charge, such as ion exchange chromatography; methods that utilize specific affinity, such as affinity chromatography (for example, methods that use a resin bound to glutathione when a polypeptide is expressed with a GST tag, a Ni-NTA resin or a Co-based resin when a polypeptide is expressed with a His tag, an anti-HA antibody resin when a polypeptide is expressed with an HA tag, or an anti-FLAG antibody-bound resin when a polypeptide is expressed with a FLAG tag); methods that utilize differences in hydrophobicity, such as reversed-phase high-performance liquid chromatography; and methods that utilize differences in isoelectric point, such as isoelectric focusing.
[0038] The third embodiment is the optical switch protein according to the first embodiment, in which two proteins selected from the VVD protein group are linked via a fluorescent protein or a bioluminescent protein. In some cases, one or more amino acid residues at the end of the VVD protein where the fluorescent protein or bioluminescent protein is linked may be deleted (see the description of the first embodiment). In the optical switch protein according to the third embodiment, a fluorescent protein or a bioluminescent protein is present between the two VVD proteins. The fluorescent protein or bioluminescent protein may be linked directly to the VVD protein, or indirectly via a linker (e.g., a peptide).
[0039] When a fluorescent protein is present between two VVD proteins, excitation of the fluorescent protein with near-infrared light (e.g., two-photon excitation) that penetrates biological tissues can induce FRET (Fluorescence Resonance Energy Transfer) from the fluorescent protein to the VVD protein, if the excitation energy emitted by the fluorescent protein is acceptable to the VVD protein, thereby inducing binding between the VVD proteins. Two-photon excitation can be used to excite fluorescent proteins with near-infrared light. In two-photon excitation, two photons with half the energy of one-photon excitation, i.e., twice the wavelength, are simultaneously absorbed by the fluorescent protein, resulting in the emission of fluorescence with the same wavelength as one-photon excitation. For example, a fluorescent protein that is excited with a wavelength of 400 nm in one-photon excitation would be excited with a wavelength of 800 nm in two-photon excitation. Therefore, using near-infrared light with a wavelength around 800 nm as excitation light has the advantage of being less susceptible to scattering within biological samples (e.g., biological tissue), enabling deeper observations. Therefore, the fluorescent protein constituting the optical switch protein according to the third embodiment is preferably one that can be two-photon excited by near-infrared light (e.g., light of approximately 650 nm to 900 nm) and that induces FRET from the fluorescent protein to the VVD protein. Such fluorescent proteins can be easily selected by those skilled in the art, and include, but are not limited to, BFP, TagBFP, mTagBFP2, mBlueberry2, mCerulean, mTurquoise, ECFP, TagCFP, Rosmarius, meleCFP, mTFP1, KCY, and meffCFP.
[0040] Furthermore, when a bioluminescent protein is present between two VVD proteins, if the energy generated by an oxidation reaction catalyzed by the bioluminescent protein in the presence of a luminescent substrate can be accepted by the VVD protein, BRET (Bioluminescence Resonance Energy Transfer) will occur from the bioluminescent protein to the VVD protein, thereby inducing binding between the VVD proteins. Examples of bioluminescent proteins that can be used here include NanoLuc, Gaussia luciferase, Renilla luciferase, and firefly luciferase.
[0041] The fourth embodiment is a method for controlling the distance between two proteins, comprising the steps of: binding (including "fusing") one VVD protein constituting the optical switch protein according to this embodiment to one of the two proteins; binding (including "fusing") the other VVD protein constituting the optical switch protein to the other of the two proteins; and irradiating the optical switch protein with light. Here, the two "proteins" are preferably proteins that interact with each other. Alternatively, the two proteins may be two split fragments generated by splitting a single protein, and the two fragments may be split so as to restore the activity of the original protein upon recombination (reassociation). The VVD protein and the protein may be bonded via a linker or the like, or may be directly bonded (fused).
[0042] The fourth embodiment can also be carried out intracellularly. Here, "cells" includes both in vitro and in vivo cells. A person skilled in the art can appropriately select a method for introducing a protein complex composed of the light-switch protein according to this embodiment and the "two proteins" according to the fourth embodiment into a cell. For example, a vector expressing the protein complex may be introduced into the cell to express the protein complex within the cell, or the protein complex may be directly introduced into the cell using a cell membrane-permeable peptide or the like. When the protein complex is to be translocated to the nucleus or intracellular organelles, the protein complex may be introduced into the cell in a state fused with a translocation signal peptide (e.g., a nuclear localization signal peptide, a mitochondrial localization signal peptide, etc.).
[0043] When this specification is translated into English and includes the singular words "a," "an," and "the," it is intended to include not only the singular but also the plural, unless the context clearly indicates otherwise. Furthermore, in this specification, the terms "similar" and "about" refer to a numerical range of ±10%. The present invention will be further explained below with reference to examples, but these examples are merely illustrative of embodiments of the present invention and do not limit the scope of the present invention.
[0044] 1. Methods 1-1. Reagents and Materials. All oligonucleotides used in plasmid construction were synthesized by Eurofines Genomics, Integrated DNA Technology, or GenScript. The mammalian cell expression vectors pcDNA3.1(+), pcDNA3.1 / V5-His A, and pEF6 / V5-His A were purchased from ThermoFisher Scientific. Plasmid construction was performed using a conventional method based on overlap extension PCR, restriction enzyme digestion of the PCR products, and ligation of the resulting double-stranded DNA with T4 DNA ligase. PrimeSTAR HS DNA Polymerase (Takara Bio, Japan) or KOD One PCR Master Mix (Toyobo) was used for PCR according to the accompanying instructions. All restriction enzymes used for DNA digestion were purchased from Takara Bio or New England BioLabs (NEB) and used according to the accompanying instructions. T4 DNA ligase Ligation high Ver.2 (Toyobo) was used for ligation according to the accompanying instructions. All constructs were verified by a DNA sequencing analysis service (Eurofines Genomics), and all plasmid constructs were purified using QIAGEN Plasmid Plus Kits (QIAGEN).
[0045] 1-2. Plasmid Construction. To construct the expression plasmid for photoactivated Cas9, sequences encoding the codon-optimized N- and C-terminal fragments of Streptococcus pyogenes Cas9 fused to the SV40 T-antigen nuclear localization signal (NLS) were amplified from Addgene plasmid (ID: 42230). Codon-optimized sequences encoding pMag and nMagHigh1 for expression in mammalian cells were synthesized by Eurofines Genomics, Integrated DNA Technology, or GenScript. The nucleotide sequences of the expression constructs for PA-Cas9_N-term, PA-Cas9_C-term, scPA-Cas9 (linked with a flexible linker), scPA-Cas9 (linked with a rigid linker), and scPA-Cas9 (direct fusion) were inserted into the HindIII and XhoI sites of the pcDNA3.1 / V5-His A vector containing a cytomegalovirus (CMV) promoter. gRNA expression vectors were constructed by inserting oligonucleotides annealed to the BbsI site of the pSPgRNA vector (ID: 47108) purchased from Addgene, containing gRNAs targeting human VEGFA, human DNMT1, human EMX1, and mouse K-ras. The target sequences and oligonucleotides used to construct the gRNA expression vectors are shown in Figure 4 and Table 1.
[0046]
[0047] For the construction of light-activated Cre, sequences fused to the N- and C-terminal fragments of Cre recombinase, codon-optimized for expression in mammalian cells, and nuclear localization signals (NLSs) were synthesized by Invitrogen or ThermoFisher Scientific. The coding sequences for pMag (SEQ ID NO: 37) and nMag (SEQ ID NO: 38), codon-optimized for expression in mammalian cells, were synthesized by Eurofines Genomics, Integrated DNA Technology, or GenScript. Light-activated Cre sequences were constructed by inserting PA-Cre and scPA-Cre into the HindIII-XbaI or HindIII-XhoI sites of the pcDNA3.1(+) vector containing the CMV promoter. For the construction of luciferase reporters to detect Cre-loxP recombinase activity, polyadenylation "stop" signal (poly(A)) repeat sequences flanking and in the same orientation as the loxP site were amplified from Addgene plasmid (ID: 22797). The sequence encoding firefly luciferase (Fluc) was amplified from the pGL4.31 vector (Promega). The loxP-stop-loxP-Fluc construct was inserted into the HindIII-XhoI sites of the pcDNA3.1(+) vector, which contains the CMV promoter.
[0048] To construct light-activated Flp, we commissioned Eurofines Genomics to synthesize N- and C-terminal fragments of Flp recombinase fused to NLSs, with codons optimized for expression in mammalian cells. The coding sequences for pMag, nMag, pMagHigh1, and nMagHigh1, codon-optimized for expression in mammalian cells, were synthesized by Eurofines Genomics, Integrated DNA Technology, or GenScript. Light-activated Flp sequences were constructed by inserting PA-Flp_N-terminal, PA-Flp_C-terminal, and scPA-Flp into the HindIII-XbaI site of the pcDNA3.1(+) vector, which contains a CMV promoter. A luciferase reporter construct for detecting Flp-FRT recombinase activity was created by replacing the two loxP sites in the loxP-stop-loxP-Fluc construct with FRT sites. The light-activated Flp construct for the Cre-dependent recombination cascade was constructed by inserting the scPA-Flp sequence into the HindIII-NotI site of the loxP-stop-loxP-Fluc reporter vector. The fluorescent reporter for detecting Flp-FRT recombinase activity was constructed by synthesizing a sequence encoding mKate2 fused to Akaluc luciferase (Eurofines Genomics) and inserting the synthesized sequence into the HindIII-NotI site of the FRT-stop-FRT-Fluc reporter vector.
[0049] To construct photoactivatable Vav, sequences encoding Lifeact-mCherry, codon-optimized for expression in mammalian cells, the P2A self-cleaving 2A peptide, the N- and C-terminal fragments of mouse Vav2, Rho GEF, pMag, and nMag were synthesized by Eurofines Genomics. The synthesized sequences were inserted into the EcoRI-XbaI site of the pEF6 / V5-His A vector containing the human EF-1α promoter. To construct two-photon photoactivatable Vav, sequences encoding pMag, mTagBFP2, and nMag were synthesized by Eurofines Genomics and inserted into the AgeI-KpnI site of the scPA-Vav construct. The nucleotide sequences of all the constructs are shown in Figures 28 to 43.
[0050] 1-2 Cell Culture HEK293T, COS-7, and NIH3T3 cells (American Type Culture Collection (ATCC)) and HeLa cells (Japanese Collection of Research Bioresources (JCRB) cell bank) were cultured in Dulbecco's Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) supplemented with 0% fetal bovine serum (Thermo Fisher Scientific), 100 unit / mL penicillin, 100 μg / mL streptomycin (Thermo Fisher Scientific), and 2 mM L-glutamine or 2 mM GlutaMAX (Thermo Fisher Scientific) at 37°C under 5% CO2. The 5-11 cell line, derived from pancreatic cancer in LSL-KrasG12D / +; LSL-Trp53R172H / +; ptf1a-Cre (KPC) mice, was established as previously described (Fuchigami et al., Scientific Reports 8:14211 (2018)). 5-11 cells were cultured in RPMI-1640 medium (Roswell Park Memorial Institute 1640 Medium) (Thermo Fisher Scientific) supplemented with 20% FBS and 1x Antibiotic-Antimycotic Mixed Solution (Nacalai Tesque) at 37°C under 5% CO2.
[0051] 1-3. Light Source For the blue light used in the cultured cell assay and in vivo mouse experiments, an LED light source (70 ± 20 nm; CCS) was used.
[0052] 1-4. Genome Editing Experiments. For indel mutation experiments mediated by non-homologous end joining (NHEJ) using HEK293K cells, cells were seeded at 100,000 cells / well in a 24-well plate (Thermo Fisher Scientific) and cultured at 37°C under 5% CO2 for 24 hours. Then, cells were transfected using Lipofectamine 3000 (Thermo Fisher Scientific) according to the manufacturer's instructions. The cDNAs encoding the NLS-N-terminal fragment of Cas9-pMag, the nMagHigh1-C-terminal fragment of Cas9-NLS, and the gRNA were transfected at a 1:1:1 ratio. The total amount of cDNA was 0.2741 μg / well. As positive and negative controls, cDNA encoding full-length Cas9 or pcDNA3.1 / V5-His A (empty vector) were transfected at a 1:1 ratio. Twenty hours after transfection, cells were incubated in the dark or under blue light irradiation (1.0 W m -2 ) for 24 hours. Genomic DNA was then extracted using the Blood Cultured Cell Genomic DNA Extraction Mini Kit (Favorgen) according to the manufacturer's instructions.
[0053] For non-homologous end-joining-mediated indel mutation experiments using HeLa cells, cells were seeded at 100,000 cells / well in a 24-well plate (Thermo Fisher Scientific) and cultured at 37°C under 5% CO2 for 96 hours. Subsequently, cells were transfected using X-tremeGENE 9 reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. The cDNAs encoding the NLS-N-terminal fragment of Cas9-pMag, the nMagHigh1-C-terminal fragment of Cas9-NLS, and the gRNA were transfected at a 1:1:1 ratio. The cDNAs encoding scPA-Cas9 and the gRNA were transfected at a 1:1 ratio. The total amount of cDNA was 0.1 μg / well. As positive and negative controls, cDNA encoding full-length Cas9 or pcDNA3.1 / V5-His A (empty vector) was transfected at a 1:1 ratio. Immediately after transfection, cells were transfected in the dark or under blue light irradiation (1.0 W m -2 ) for 48 hours. Genomic DNA was then extracted using a QuickExtract DNA Solution kit (Lucigen) according to the manufacturer's instructions.
[0054] For non-homologous end-joining-mediated indel mutation experiments using 5-11 cells, cells were seeded at 100,000 cells / dish in 10 cm culture dishes and pre-cultured at 37°C under 5% CO2 for 24 hours. Then, 400,000 cells per cuvette were transfected by nucleofection using the SG cell line 4D-Nucleofector X kit S (Lonza) and the EN-158 program according to the manufacturer's instructions. The cDNAs encoding the NLS-N-terminal fragment of Cas9-pMag, the nMagHigh1-C-terminal fragment of Cas9-NLS, and the gRNA were transfected at a 1:1:1 ratio. The cDNAs encoding scPA-Cas9 and gRNA were transfected at a 2:1 ratio. The total amount of cDNA was 2.0 μg / well. As a positive and negative control, cDNA encoding full-length Cas9 or pcDNA3.1 / V5-His A (empty vector) was nucleofected at a 2:1 ratio. After nucleofection, the cells were incubated in a nucleocuvette for 10 minutes at room temperature. Then, the cells were suspended in pre-warmed RPMI-1640 medium. The suspended cells were seeded into a 96-well plate at 40,000 cells / well. Immediately after seeding, the cells were incubated in the dark or under blue light irradiation (1.0 W m -2 ) for 48 hours, after which genomic DNA was collected.
[0055] 1-5. Genomic PCR. Genomic regions containing nuclease target sites were amplified by touchdown PCR using PrimeSTAR HS DNA Polymerase (TaKaRa Bio). Touchdown PCR was performed under the following conditions: Initial denaturation: 98°C for 3 minutes; Touchdown PCR (10 cycles): Denaturation (98°C for 10 minutes), annealing (72°C, decreased by 1°C per cycle, 30 seconds), extension (72°C for 1 minute); Conventional PCR (25 cycles): Denaturation (98°C for 10 seconds), annealing (62°C for 30 seconds), extension (72°C for 1 minute); Final extension reaction: 72°C for 3 minutes. The sequences of the PCR primers are listed in Table 2. The amplified PCR products were purified using FastGene Gel / PCR Extraction Kits (Nippon Genetics, Japan).
[0056]
[0057] 1-6. Sequencing analysis The PCR products prepared as described above were subcloned into pcDNA3.1 / V5-His A. Plasmids were isolated and Sanger sequenced. TIDE analysis (https: / / tide.deskgen.com / ) was performed using the purified PCR products.
[0058] 1-7. Site-specific recombination experiments. For luciferase assays, COS-7 or NIH3T3 cells were seeded into 96-well clear, flat-bottom, black-walled microplates (Greiner Bio-One, Austria) at 10,000 or 15,000 cells / well and cultured at 37°C under 5% CO2 for 24 hours. The cells were transfected with cDNA encoding PA-Cre, scPA-Cre, PA-Flp, or scPA-Flp and a luciferase reporter (loxP-stop-loxP Fluc reporter or FRT-stop-FRT Fluc reporter) at a 1:20 ratio using Lipofectamine 3000 reagent at 37°C. The total amount of DNA used was 0.1 μg / well. 24 hours after transfection, the cells were incubated in the dark or under blue light irradiation (1.0 W m -2 Immediately before the luciferase assay, the medium was replaced with HBSS (Hanks' balanced salt solution) (Thermo Fisher Scientific) containing 0.2 mM D-luciferin potassium salt (Wako). Bioluminescence was measured at room temperature using a Centro XS 3 Luminescence was measured for 10 seconds per well using an LB 960 plate-reading luminometer (Berthold Technologies).
[0059] For the control experiments shown in Figures 9 and 11, COS-7 cells were seeded into 96-well clear, flat-bottom, black-walled microplates at 10,000 or 15,000 cells / well and cultured at 37°C under 5% CO2 for 24 hours. The cells were transfected with cDNA encoding PA-Cre or scPA-Cre and a loxP-stop-loxP Fluc reporter at a 1:10 ratio using X-tremeGENE 9 reagent at 37°C. The total amount of DNA used was 0.05 μg / well. The cells were transfected with cDNA encoding PA-Flp or scPA-Flp and a FRT-stop-FRT Fluc reporter at a 1:10 ratio using Lipofectamine 3000 reagent at 37°C. The total amount of DNA used was 0.1 μg / well. Twenty-four hours after transfection, the cells were incubated in the dark or under blue light (1.0 W m -2 Immediately before the luciferase assay, the medium was replaced with HBSS medium containing 0.2 mM D-luciferin potassium salt. Bioluminescence was measured at room temperature using a Centro XS 3 Each well was measured for 10 seconds using an LB 960 plate-reading luminometer.
[0060] For the irradiation intensity-dependent experiments shown in Figures 9 and 11, COS-7 cells were seeded at 10,000 or 15,000 cells / well in a 96-well clear, flat-bottom, black-walled microplate and cultured at 37°C for 24 hours under 5% CO2. The cells were transfected with cDNA encoding scPA-Cre and a loxP-stop-loxP Fluc reporter at a 1:10 ratio using X-tremeGENE 9 reagent at 37°C. The total amount of DNA used was 0.05 μg / well. The cells were transfected with cDNA encoding scPA-Flp and a FRT-stop-FRT Fluc reporter at a 1:10 ratio using Lipofectamine 3000 reagent at 37°C. The total amount of DNA used was 0.1 μg / well. Twenty-four hours after transfection, cells were incubated in the dark or under blue light irradiation (0.01, 0.03, 0.1, 0.3, 1.0, 1.6, and 3.3 W m -2 , or 0.01, 0.03, 0.05, 0.1, 0.3, 1.0, 1.6 and 3.0 W m -2 Immediately before the luciferase assay, the medium was replaced with HBSS medium containing 0.2 mM D-luciferin potassium salt. Bioluminescence was measured at room temperature using a Centro XS 3 Luminescence was measured for 10 seconds per well using an LB 960 plate-reading luminometer (Berthold Technologies, Germany).
[0061] For the irradiation time-dependent experiments shown in Figures 9 and 11, COS-7 cells were seeded into 96-well clear, flat-bottom, black-walled microplates at 10,000 or 15,000 cells / well and cultured at 37°C under 5% CO2 for 24 hours. The cells were transfected with cDNA encoding scPA-Cre and a loxP-stop-loxP Fluc reporter at a 1:10 ratio using X-tremeGENE 9 reagent at 37°C. The total amount of DNA used was 0.05 μg / well. The cells were transfected with cDNA encoding scPA-Flp and a FRT-stop-FRT Fluc reporter at a 1:10 ratio using Lipofectamine 3000 reagent at 37°C. The total amount of DNA used was 0.1 μg / well. Twenty-four hours after transfection, the cells were exposed to blue light (1.0 W m ) in the dark. -2 ) for 30 seconds, 3 minutes, 30 minutes, and 1 hour, and then cultured in the dark or under blue light (1.0 W m -2 Immediately before the luciferase assay, the medium was replaced with HBSS medium containing 0.2 mM D-luciferin potassium salt. Bioluminescence was measured at room temperature using a Centro XS 3 Luminescence was measured for 10 seconds per well using an LB 960 plate-reading luminometer (Berthold Technologies, Germany).
[0062] For the recombination cascade experiment shown in Figure 15, COS-7 cells were seeded at 15,000 cells / well in a 96-well clear, flat-bottom, black-walled microplate and cultured at 37°C for 24 hours under 5% CO2. Cells were transfected with iCre-encoding cDNA or pcDNA3.1 (+) empty vector and scPA-Flp-encoding cDNA, along with the Akaluc luciferase reporter, at a 1:1:9 ratio using Lipofectamine 3000 reagent at 37°C. The total amount of DNA used was 0.1 μg / well. Cells were transfected with PA-Flp-encoding cDNA or scPA-Flp-encoding cDNA and the FRT-stop-FRT Fluc reporter at a 1:10 ratio using Lipofectamine 3000 reagent at 37°C. The total amount of DNA used was 0.1 μg / well. Twenty-four hours after transfection, cells were incubated in the dark or under blue light irradiation (1.0 W m -2 Immediately before the luciferase assay, the medium was replaced with HBSS medium containing 0.2 mM D-luciferin potassium salt. Bioluminescence was measured at room temperature using a Centro XS 3 Luminometer readings were taken for 10 seconds per well using an LB 960 plate-reading luminometer.
[0063] 1-8. In vivo experiments using mice. Experiments using mice were performed in accordance with the Guide for the Care and Use of Laboratory Animals. In all experiments, 6-week-old female Rosa26-CreER mice were used. T2 Mouse (CreER T2 Mice (kindly provided by Dr. Tyler Jacks, Massachusetts Institute of Technology) were used. Hair on the abdominal surface was removed with a hair removal cream. The depilated mice were allowed to rest in their cages for at least 12 hours. Six hours before HTV (hydrodynamic tail vein) injection of the plasmid cDNA, CreER T2To activate the recombinase, mice were intraperitoneally injected with 100 μg / g body weight (g) of tamoxifen (Sigma). Then, HTV injections of the cDNA encoding pcDNA3.1-loxP-stop-loxP-scPA-Flp and the cDNA encoding pcDNA3.1-FRT stop-FRT-Akaluc-mKate2 were performed into mice at a 1:1 ratio using TransIT-QR Hydrodynamic Delivery Solution (Mirus Bio LLC) according to the manufacturer's instructions. The total amount of DNA injected was 40 μg / mouse. The total volume of the injected solution was 0.1 mL / mouse. After DNA injection, the mice were placed in a cage and kept in the dark for 6 hours, after which they were exposed to an LED light source (470 ± 20 nm; 132 W m -2 ) and irradiated with light for 18 hours. 24 hours after DNA injection, fluorescent imaging of the mice was performed. The livers of the DNA-injected mice were isolated using standard surgical techniques and immersed in PBS solution. Fluorescent images of the isolated livers were then captured using an all-in-one fluorescent microscope, BZ-X710 (KEYENCE).
[0064] 1-9. Live Cell Imaging. Glass-bottom dishes (Cat. #D11530H, Matsunami) were treated with 25 mg / mL human fibronectin (BD Biosciences) for 10 minutes at room temperature and washed twice with 2 mL of Mili-Q water. To perform cell migration assays using confocal imaging, NIH3T3 cells were seeded onto 35 mm glass-bottom dishes (glass area = 14 mm) at 2,000 cells / dish and cultured for 24 hours at 37°C under 5% CO2. Cells were transfected with cDNA encoding Lifeact mCherry and scPA-Vav or 2PscPA-Vav using Lipofectamine 3000 reagent at 37°C. The total amount of transfected DNA was 0.1 μg / dish. Twenty-four hours after transfection, the medium was replaced with Leibovitz's L-15 phenol red-free medium containing 5% FBS and 2 mM GlutaMAX. Imaging was performed using a ×63 / 1.05 numerical aperture (NA) silicon oil immersion objective (Carl Zeiss) on the stage of an LSM confocal laser scanning microscope (Carl Zeiss) equipped with a heated stage adapter (Tokai Hit). Fluorescence images of mCherry were acquired using a multiline HeNe laser (543 nm). One-photon blue light illumination was performed with a 1 mW multiline argon laser (488 nm). Two-photon excitation of mTagBFP2 was performed with a 25 mW multiline Chameleon laser (808 nm).
[0065] 1-10. Quantitative Analysis of Cell Area Spreading. Fluorescence images of NIH3T3 cells expressing Lifeact-mCherry and scPA-Vav or 2PscPA-Vav were acquired 15 minutes before light exposure (dark), immediately before light exposure (before), and 15 minutes after light exposure (after). The acquired fluorescence images were converted to binary data based on the mCherry fluorescence intensity using Image-J software. The data were used to calculate the percentage of cell area spread between the dark and before or before and after images.
[0066] 1-11. Reproducibility and statistical analysis No power tests were performed in the cell culture and mouse experiments. No samples or animals were excluded from the analysis. Randomization was performed in the cell culture and mouse experiments. No blinding was performed in the cell culture and mouse experiments.
[0067] 2. Results 2-1. Development of scMagnet Based on the split-Cas9 endonuclease and magnet system (Kawano et al., Nat. Commun. 6:6256 (2015)), we developed a two-molecule photoactivatable Cas9 (PA-Cas9) (Nihongaki et al., Nat. Biotechnol. 33:755-760 (2015)) useful for optogenetic genome editing (see Figures 2a, 3, and 4). First, we measured the efficiency of photoinduction of conventional PA-Cas9 activity using the tracking of indels by decomposition (TIDE) assay (Brinkman et al., Nucleic Acids Res. 42:e168 2014). Under blue light irradiation, HEK293T cells expressing PA-Cas9 targeting the human VEGFA gene showed a high indel mutation rate (>25%), comparable to that of cells expressing full-length Cas9 (Fig. 1b). PA-Cas9 also efficiently introduced indel mutations into the human DNMT1 and EMX1 genes in a light-dependent manner in HEK293T cells (Fig. 5).
[0068] In contrast, HeLa cells expressing PA-Cas9 targeting the human VEGFA gene showed a very low indel mutation rate (<1%) under both dark and blue light conditions (Fig. 2d). Furthermore, similar to the case of the human VEGFA gene, HeLa cells expressing PA-Cas9 targeting the human DNMT1 and EMX1 genes also showed a low indel mutation rate, almost equivalent to that of cells expressing the pcDNA3.1 empty vector (Fig. 5). Because HeLa cells generally express lower levels of foreign proteins than HEK293T cells (Rio et al., Science 227:23-28 (1985)), we hypothesized that the low photoinduction efficiency of PA-Cas9 in HeLa cells was due to the low expression level of PA-Cas9 in the cells.
[0069] To overcome the problem of bimolecular photoswitching systems such as conventional magnet systems (for example, conventional magnet systems consist of two molecules, pMag and nMag), namely, that the light induction efficiency depends on the concentration of the magnet protein in the cell, we considered linking pMag and nMag in series, as shown in Figure 2c. This series linking of two magnet protein molecules is called scMagnet (single-chain-based Magnet).
[0070] Each Cas9 fragment was ligated to pMag and nMag, respectively, and then tandemly linked to create scPA-Cas9 (single-chain-based photoactivatable Cas9) (Fig. 2c). The efficiency of photoinduction of genome editing (indel introduction into the target genomic region) was measured. As expected, HeLa cells expressing scPA-Cas9 targeting the human VEGFA gene experienced high indel introduction rates (>10%) in the VEGFA gene (Fig. 2d). In contrast, in the dark, the indel frequency was low (1%-4%), comparable to that of the pcDNA3.1 empty vector. These results demonstrate that the photoinduction efficiency of scPS-Cas9 activity in HeLa cells was approximately 18.1-fold higher than that of PA-Cas9, demonstrating a significant improvement. The scPA-Cas9's unique features of high genome editing efficiency under blue light irradiation and minimal genome editing in the dark were also observed when other genes (human DNMT1 and EMX1 genes) were targeted in HeLa cells (Fig. 6). These results demonstrate that scMagnet functions as a single-molecule photoswitching system with low leakage activity in the dark (binding activity in the dark) and extremely high rebinding induction rate under blue light irradiation.
[0071] 2-2. Verification of scMagnet Function in Vitro 2-2-1. Versatility of scMagnet Next, we investigated whether the scMagnet system could be applied to the optogenetic recombination of split proteins other than split Cas9. Previously, we developed photoactivatable Cre recombinase (PA-Cre) (Kawano et al., Nat. Chem. Biol. 12:1059-1064 (2016)) and photoactivatable Flp recombinase (PA-Cre) (Jung et al., Nat. Commun. 10:314 (2019)) based on the Magnet system. Therefore, to examine the versatility of the scMagnet system, we constructed single-stranded photoactivatable Cre recombinase and single-stranded photoactivatable Flp recombinase based on scMagnet and examined their activity (Figures 7a and c, 8, and 10). First, we compared the light-induced efficiency of scPA-Cre or scPA-Flp with that of A-Cre or PA-Flp using luciferase reporter assays in COS-7 cells. Similar to PA-Cre, scPA-Cre exhibited highly efficient light-induced recombination activity (up to 122-fold) under continuous light, short-pulse light, and different light intensities, without leakage in the dark (Fig. 9). Similarly to PA-Flp, scPA-Flp exhibited highly efficient light-induced recombination activity (up to 122-fold) without leakage in the dark (Fig. 11). These results demonstrate that scMagnet can induce optogenetic recombination of not only split Cas9 endonuclease but also other split proteins, including split Cre recombinase and split Flp recombinase.
[0072] Next, we examined the effect of suppressing the expression levels of scPA-Cre and PA-Cre in COS-7 cells on the recombination efficiency of scPA-Cre and PA-Cre. The transfection amounts of the scPA-Cre-encoding plasmid DNA and the PA-Cre-encoding plasmid DNA were reduced from 9.1% (experimental conditions for the data shown in Figure 9) to 4.8% of the total transfection amount. In this case, scPA-Cre exhibited higher light-induced recombination activity than PA-Cre under blue light irradiation, even at reduced expression levels (Figure 7b). Similar results were observed when using split Flp recombinase (Figure 7d). Furthermore, similar results were obtained when using NIH3T3 cells, which express lower levels of exogenous gene protein than COS-7 cells (Figure 12). These results demonstrate that the scMagnet system can efficiently control split protein recombination even in cells with low levels of exogenous gene protein expression.
[0073] 2-2-2. Effect of linker length or amino acid deletion at the linker between pMag and nMag on activity We investigated the effect of the linker length connecting pMag and nMag on the efficiency of photoinduction by the scMagnet system. scPA-Cre was constructed by linking pMag and nMag with a flexible peptide linker (a linker consisting of 0 to 20 amino acid residues) (Fig. 13a). The photoinduction efficiency of recombination activity of scPA-Cre without an inserted linker was compared with that of scPA-Cre with an inserted flexible linker (Fig. 13a). "iCre" is a control in which a nuclear localization signal is linked to full-length Cre and is not responsive to blue light. "Reporter only" is a control containing only a bioluminescence reporter, without using either scPA-Cre or iCre. As a result, all scPA-Cre genes with flexible linkers exhibited recombination activity with photoinduction efficiencies comparable to those of unlinked scPA-Cre genes, regardless of linker length (Fig. 13a).These characteristics of the scMagnet system were also confirmed in genome editing using Cas9 (Fig. 14).
[0074] Next, we found that the leakage activity of scPA-Cre (without a linker) was further suppressed by deleting several amino acid residues at the C-terminus of pMag (Fig. 13b). Because deleting amino acid residues at the C-terminus of pMag tends to reduce the efficiency of light-induced recombination, the number of amino acid residues to be deleted is not particularly limited, but is preferably around six.
[0075] We further investigated the effect of deleting several amino acid residues at the N-terminus of nMag on the activity. The enzymatic activity of scPA-Cre, which was formed by directly linking the C-terminus of pMag and the N-terminus of nMag to form a single molecule, and of scPA-Cre mutants (Δ1 to Δ19) in which single amino acid residues were deleted at the N-terminus of nMag were introduced, were measured in the dark and under blue light irradiation (Fig. 15). The amino acids around the junction between pMag and nMag are shown in Fig. 15. "iCre" is a control in which a nuclear localization signal is linked to full-length Cre and has no blue light responsiveness. "Reporter only" is a control containing only the bioluminescence reporter, without scPA-Cre or iCre. The measurements revealed that each scMagnet mutant, in which one amino acid residue from the 1st to 19th amino acids of nMag was deleted, exhibited low leakage activity in the dark and maintained high blue light responsiveness.
[0076] We further investigated the Cre recombination activity of nMag by further stepwise deletion of amino acids at the N-terminus (Fig. 16). The amino acid sequence and domain structure of nMag are shown in Fig. 16A. An scPA-Cre mutant was constructed by introducing an nMag mutant lacking the amino acids marked with a Δ in the figure, and its Cre recombination activity was evaluated (Fig. 16B). We also constructed an scPA-Cre mutant (pMag+nMag-Latch-NCap-Hinge) by introducing an nMag mutant containing only Latch-NCap-Hinge, and its Cre recombination activity was evaluated. Figure 16B shows the enzymatic activity of single-chain photoactivatable Cre recombinase (scPA-Cre, pMag+nMag), in which the N-terminal and C-terminal fragments of split-Cre were introduced at both ends of scMagnet. The enzymatic activity of scPA-Cre mutants (Δ35, Δ56, Δ71, or Δ119) with large deletions of the N-terminus of nMag was also measured. The enzymatic activity of the scPA-Cre mutant (Latch-NCap-Hinge) in which only the N-terminal region of nMag was introduced was also measured. The enzymatic activity of the scPA-Cre mutant (ΔnMag) in which only pMag was introduced without nMag was also measured. The results are shown in Figure 16B. "iCre" is a control in which a nuclear localization signal is linked to full-length Cre and is not responsive to blue light. "Reporter only" is a control containing only the bioluminescence reporter, without scPA-Cre or iCre. The measurements showed that the dark leakage activity of the scMagnet mutant was low even when the first 35 amino acids of nMag were deleted, but that the dark leakage activity of the scMagnet mutant was significantly increased when the first 56 amino acids of nMag were deleted. These results suggest that the leakage activity of scPA-Cre introduced with an nMag mutant in which amino acid residues on the N-terminus are deleted changes from "low" to "high" by deleting any of the amino acid residues from the N-terminal amino acid residues of nMag, from 36 to 55.
[0077] Next, we measured the enzymatic activity of scPA-Cre and the Cre recombination activity of scPA-Cre mutants containing partial deletions of the C-terminus of pMag and the N-terminus of nMag, respectively, in the dark and under blue light irradiation (Figure 17). "iCre" is a control in which a nuclear localization signal is linked to full-length Cre and is not responsive to blue light. "Reporter only" is a control containing only the bioluminescence reporter, without scPA-Cre or iCre. As can be seen from Figure 17, by linking a pMag mutant with C-terminal deletions and an nMag mutant with N-terminal deletions, we were able to obtain scMagnet mutants that exhibited low leakage activity in the dark and high responsiveness (recombination activity) under blue light irradiation.
[0078] 2-3. Verification of scMagnet Action in Vivo Next, the in vivo action of the scMagnet system was verified using scPA-Flp. First, a recombination cascade system based on light-induced recombination of scPA-Flp, whose expression is induced by Cre recombination, was constructed (Fig. 18a). First, using this system, it was confirmed in vitro that scPA-Flp recombination is induced with high efficiency not only by blue light irradiation but also by Cre expression in COS-7 cells (Fig. 18b). Next, to operate the recombination cascade system in vivo, we used a Rosa26-activated CreER gene, which ubiquitously expresses tamoxifen-inducible Cre recombinase. T2Experiments were performed using a mouse model (Ventura et al., Nature 445:661-665 (2007)). Plasmid DNA encoding floxed-stop scPA-Flp and plasmid DNA encoding the FRT-floxed-stop mKate2 reporter were introduced into mouse livers using the hydrodynamic tail vein injection method (Liu et al., Gene Ther. 6:1258-1266 (1999)) (Fig. 19a and b, Fig. 20). The DNA-injected mice were housed in the dark or under blue light for 18 hours. When housed under blue light, mKate2 fluorescence was detected in the livers of tamoxifen-injected mice (Fig. 19c, Fig. 20). In contrast, no fluorescence was detected in the livers of mice housed in the dark (Fig. 19c, Fig. 20). No mKate2 fluorescence was detected in mice housed in the dark or under blue light without tamoxifen injection. These results indicate that scPA-Flp functions well in vivo in the presence of Cre and blue light irradiation (Fig. 19c, Fig. 20). These results demonstrate that scMagnet functions in vivo even under non-invasive blue light irradiation.
[0079] 2-4. Examination of the reversibility of scMagnet function. We investigated whether scMagnet functions reversibly in a blue light-induced manner using the Rho-family guanine exchange factor (GEF) Vav2 protein, which is required for cell spreading (Fig. 21). First, we constructed a scMagnet using photoactivated Vav2 (referred to as scPA-Vav) (Fig. 22a, b). Using Lifeact-mCherry as a fluorescent biosensor to detect actin polymerization, we evaluated the activity of scPA-Vav before and after blue light irradiation in a cell area expansion assay (Fig. 23). When NIH3T3 cells expressing scPA-Vav were maintained in the dark for 15 min, there was little change in cell area, whereas 15 min of blue light irradiation induced significant cell area expansion (Fig. 22c, d, Fig. 24). On the other hand, in the presence of EHop-016, which inhibits the binding of Vav2 to Racl1, cell area expansion was not observed, similar to that observed when cells were maintained in the dark without EHop-016 (Fig. 22e and f, Fig. 24). These results indicate that scPA-Vav does not induce leak activity in the dark and effectively activates Vav2 signaling in a blue light-dependent manner.
[0080] Next, to examine whether scPA-Vav functions reversibly, we irradiated scPA-Vav-expressing cells with blue light and then maintained them in the dark. As a result, scPA-Vav induced cell extension after 15 minutes of blue light irradiation, but the cell extension disappeared after 15 minutes of dark maintenance (Fig. 22g). This result indicates that scMagnet can reversibly control the binding and dissociation of split proteins.
[0081] 2-5. Control of the scMagnet System by Two-Photon Excitation To operate the scMagnet system in biological tissues, two-photon excitation with long-wavelength near-infrared light is expected to enable more efficient activation of scMagnets deeper in biological tissues than single-photon excitation. Furthermore, two-photon excitation microscopy offers higher spatiotemporal resolution than single-photon excitation microscopy, allowing for more precise control of protein activity. Therefore, we attempted to activate scMagnets by two-photon excitation. The activation efficiency of flavin-binding photoswitches, including the Magnet system, is very low due to the small two-photon absorption cross-section of the flavin cofactor (Kinjo et al., Nat. Methods 16:1029-1036 (2019)). Therefore, to date, there have been no successful attempts to control the optogenetic recombination of split proteins by two-photon excitation. Therefore, we considered applying two-photon excitation activation based on the principle of fluorescence resonance energy transfer (FRET) (Kinjo et al., Nat. Methods 16:1029-1036 (2019); Kinjo et al., ACS Chem. Biol. 15:2848-2853 (2020)) to the scMagnet system. The scMagnet system enables efficient optogenetic control by linking pMag and nMag with a flexible linker (see Figure 2c, Figures 7a and 7b, etc.). Therefore, we inserted the fluorescent protein mTagBFP2 into the linker connecting pMag and nMag, allowing it to function as a FRET donor (Figure 25).
[0082] Because the distance between the two chromophores significantly affects FRET efficiency, a shorter distance between mTagBFP2 and the Magnet system (pMag and nMag) is desirable. Based on the structural model of mTagBFP2 (aa 1-237) and the Magnet system, we determined that the N-terminal domain (aa 1-6) and the C-terminal domain (aa 229-237) of mTagBFP2 could be deleted. Therefore, we created a two-photon-excited Vav2 (2PscPA-Vav) using a scMagnet in which ΔmTagBFP2 (aa 7-228) was inserted between pMag and nMag (Figure 25b and c).
[0083] First, to demonstrate the photoresponsiveness of 2PscPA-Vav, we performed a cell spreading assay using one-photon excitation with 488 nm blue light. NIH3T3 cells expressing 2PscPA-Vav showed highly efficient light-induced cell area spreading (Fig. 25d, Fig. 26). Next, we examined the photoresponsiveness of 2PscPA-Vav using two-photon excitation microscopy. Following two-photon excitation with 808 nm near-infrared light, NIH3T3 cells expressing 2PscPA-Vav showed significant cell area spreading compared to cells maintained in the dark (Fig. 25e and f, Fig. 26). The efficiency of cell area spreading by two-photon excitation was comparable to that by one-photon excitation. On the other hand, two-photon excitation (15 min) of NIH3T3 cells expressing scPA-Vav did not induce cell area spreading (Fig. 25g, Fig. 27). These results indicate that 2PscMagnet is activated by two-photon excitation, whereas scMagnet is not activated by two-photon excitation.
[0084] The present invention provides a photoswitch protein that can precisely control binding and dissociation by turning light irradiation on and off. The photoswitch protein of the present invention can efficiently control the binding and dissociation of various proteins within cells in vitro and in vivo. Therefore, it is expected to be used in fields such as life science research and medical fields for the treatment of diseases.
Claims
1. A protein in which the C-terminus of the protein (a) below is directly or indirectly linked to the N-terminus of the protein (b): (a) a protein comprising an amino acid sequence having 80% or more sequence identity with an amino acid sequence in which X consecutive amino acid residues from the C-terminus residue to the N-terminus of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36 are deleted, where X is an integer between 0 and 6. (b) a protein comprising an amino acid sequence having 80% or more sequence identity with an amino acid sequence in which Y consecutive amino acid residues from the N-terminus residue to the C-terminus of the amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 36 are deleted, where Y is an integer between 0 and 55. However, when X of the protein (a) is 0, Y of the protein (b) is an integer between 1 and 55, and when Y of the protein (b) is 0, X of the protein (a) is an integer between 1 and 6.
2. The protein according to claim 1, wherein, in the amino acid sequence of the protein of (a), the amino acids corresponding to the 52nd and 55th amino acids in the amino acid sequence represented by SEQ ID NO:1 are substituted with arginine, or the amino acids corresponding to the 16th and 19th amino acids in the amino acid sequence represented by SEQ ID NO:36 are substituted with arginine, and, in the amino acid sequence of the protein of (b), the amino acid corresponding to the 52nd amino acid in the amino acid sequence represented by SEQ ID NO:1 is substituted with aspartic acid and the amino acid corresponding to the 55th amino acid in the amino acid sequence represented by SEQ ID NO:36 is substituted with aspartic acid and the amino acid corresponding to the 16th amino acid in the amino acid sequence represented by SEQ ID NO:36 is substituted with aspartic acid and the amino acid corresponding to the 19th amino acid in the amino acid sequence represented by SEQ ID NO:36 is substituted with glycine.
3. The protein according to claim 1, characterized in that the C-terminus of the protein (a) and the N-terminus of the protein (b) are linked via a polypeptide.
4. The protein of claim 3, wherein the polypeptide is a fluorescent protein or a bioluminescent protein.
5. The protein described in claim 4, wherein the fluorescent protein is any one of BFP, TagBFP, mTagBFP2, mBlueberry2, mCerulean, mTurquoise, ECFP, TagCFP, Rosmarius, meleCFP, mTFP1, KCY, meffCFP, GFP, YFP, Venus, mCherry and iRFP.
6. The protein of claim 4, wherein the bioluminescent protein is any one of NanoLu, Gaussia luciferase, Renilla luciferase and firefly luciferase.
7. A nucleic acid encoding a protein according to any one of claims 1 to 6.
8. A method for controlling the distance between two proteins, comprising the steps of: binding a protein (a) to one of the two proteins described in any one of claims 1 to 6; binding a protein (b) to the other of the two proteins; and irradiating the protein described in any one of claims 1 to 6 with light.
9. The method of claim 8, wherein the two proteins are interacting proteins.
Citation Information
Patent Citations
Protein set for light-dependently forming dimer
JP2015165776A
Set of polypeptides used for light-dependent genetic recombination
JP2018174774A
Set of polypeptides exhibiting nuclease activity or nickase activity with dependence on light or in presence of drug or suppressing or activating expression of target gene
WO2016167300A1
Optically controlled virus protein, gene thereof, and virus vector containing said gene
WO2019013258A1
